" However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition", {"entities": [[61, 101, "CHALLENGE"], [106, 120, "CHALLENGE"]]}
"Large-scale whole genome and exome resequencing studies have revealed that humans have a high level of deleterious rare variation, which has important implications for the design of future pharmacogenetics studies", {"entities": [[0, 24, "TECHNIQUE"], [29, 47, "TECHNIQUE"]]}
" This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations", {"entities": [[6, 20, "CHALLENGE"], [22, 37, "CHALLENGE"], [43, 58, "CHALLENGE"]]}
" Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics", {"entities": [[16, 57, "CHALLENGE"]]}
" Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing or by PCR restriction fragment length polymorphism", {"entities": [[120, 123, "TECHNIQUE"]]}
" Here we developed a novel, rapid Allele-Specific PCR method for CDA rs2072671 genotyping", {"entities": [[50, 53, "TECHNIQUE"]]}
" A total of 332 Romanian individuals were genotyped for the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms using the PCR-RFLP technique", {"entities": [[124, 132, "TECHNIQUE"]]}
" Furthermore, genotyping for CYP3A5*3 and CYP3A5*6 was performed by PCR-RFLP", {"entities": [[68, 76, "TECHNIQUE"]]}
" The SmartAmp method enables us to detect genetic polymorphisms or mutations in target genes within 30-40 min without DNA isolation and PCR amplification", {"entities": [[136, 139, "TECHNIQUE"]]}
" Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important", {"entities": [[32, 35, "TECHNIQUE"], [41, 58, "TECHNIQUE"]]}
" The present study examined two polymorphisms of GRIN1, rs11146020 (G1001C) and rs1126442 (G2108A), in 100 male Thai METH-dependent patients and 103 healthy controls using PCR-RFLP techniques", {"entities": [[172, 180, "TECHNIQUE"]]}
" Using a PCR array for 84 apoptosis genes, cantharidin treatment upregulated gene expression of caspase-1 and nerve growth factor receptor, but downregulated mRNA expression of Bcl-2 like protein 10, Fas ligand, and tumor necrosis factor-\u03b1", {"entities": [[9, 12, "TECHNIQUE"]]}
" RT-PCR analysis also confirmed the down-regulation of SKA2 and BUB1B, and the up-regulation of PPP1R15A, SQSTM1, HSPA1B, and DDIT4 by OGE treatment", {"entities": [[1, 7, "TECHNIQUE"]]}
" DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method", {"entities": [[115, 121, "TECHNIQUE"]]}
" Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods", {"entities": [[129, 132, "TECHNIQUE"]]}
" Here we developed a modified PR-PCR method using a ddNTP-blocked primer and a mixture of DNA polymerases with and without the 3'-5' proofreading function", {"entities": [[30, 36, "TECHNIQUE"]]}
" The modified PR-PCR method is quite capable of detecting various mutation types, including point mutations and insertions/deletions (indels), and allows discrimination amplification when the mismatch is located within the last eight nucleotides from the 3'-end of the ddNTP-blocked primer", {"entities": [[14, 20, "TECHNIQUE"]]}
" Current technologies for detecting the variants of these genes are mainly based on real-time PCR", {"entities": [[94, 97, "TECHNIQUE"]]}
"521T>C) SNP was performed with allele-specific polymerase chain reaction, whilst polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping the SLCO1B1 rs2306283 (c", {"entities": [[149, 157, "TECHNIQUE"]]}
" Whole blood was used to identify SNPs in ABCB1, MRP2, CYP2B6, CYP2A6, UGT2B7, NR1I2 (PXR), NR1I3 (CAR) and HNF4\u03b1 by real-time PCR", {"entities": [[127, 130, "TECHNIQUE"]]}
" In the second part of the study, consensus real-time polymerase chain reaction (RT-PCR) (Takara Bio Inc", {"entities": [[81, 87, "TECHNIQUE"]]}
" All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test", {"entities": [[71, 77, "TECHNIQUE"], [120, 126, "TECHNIQUE"]]}
" In addition, a significant degree of concordance was detected between HC2 and concensus RT-PCR methods (Cohen's kappa: 0", {"entities": [[89, 95, "TECHNIQUE"]]}
" Finally, the newly predicted miRNAs for tamoxifen and metformin were experimentally validated in MCF-7 and MDA-MB-231 breast cancer cell lines via qRT-PCR assays", {"entities": [[148, 155, "TECHNIQUE"]]}
" TPMT activity was measured by using a non-extraction HPLC method and genotype for the C3435T polymorphism of MDR1 gene was determined in 215 unrelated IBD patients including of 85 males and 130 females and 212 unrelated healthy individuals consisted of 96 males and 116 females as control group by PCR-RFLP in Iran's western population", {"entities": [[39, 58, "TECHNIQUE"]]}
" The device combines a blood lysis chamber, a cross-flow filter, a T-junction mixer, and a microreactor for quantitative polymerase chain reaction (qPCR)", {"entities": [[148, 152, "TECHNIQUE"]]}
" Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays", {"entities": [[67, 83, "TECHNIQUE"], [90, 101, "TECHNIQUE"], [106, 134, "TECHNIQUE"]]}
" Genotyping was conducted by the QuantStudio 12K Flex Real-Time PCR System using a custom open array chip with metabolism, transport, and transcription factor polymorphisms of interest to cisplatin disposition and toxicity", {"entities": [[33, 74, "TECHNIQUE"]]}
" Frequency distribution of SULT1A1 copy number (CN) in 157 healthy Indian individuals was assessed using florescent-based quantitative PCR assay", {"entities": [[135, 144, "TECHNIQUE"]]}
" Genotyping was performed by TaqMan real-time polymerase chain reaction (PCR) (pharmacokinetics genes: cytochrome P450 2D6 (CYP2D6) *4 (rs3892097), *5 (gene deletion), *10 (rs1065852) and *41 (rs28371725), ATP-binding cassette transporter B1 (ABCB1) 2677\u00a0G>T/A (rs2032582) and 3435C>T (rs1045642) and pharmacodynamics genes: dopamine receptor D2 (DRD2) Tag-SNP (C>T) (rs4436578), DRD2 Tag1A (C>T) (rs1800497), leptin gene (LEP) -2548G>A (rs7799039), ghrelin gene (GHRL) -604G>A (rs27647) and brain-derived neurotrophic factor (BDNF) 196G>A (rs6265))", {"entities": [[29, 71, "TECHNIQUE"]]}
" PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented", {"entities": [[1, 4, "TECHNIQUE"], [9, 26, "TECHNIQUE"]]}
" DNA was extracted from buccal swabs obtained from 636 non-related Southeastern European Caucasian individuals and was analyzed by real-time PCR", {"entities": [[131, 144, "TECHNIQUE"]]}
" Polymorphism genotypes were determined by real-time PCR using validated assays", {"entities": [[43, 56, "TECHNIQUE"]]}
" Genotypes were determined by means of Taq Man probes (qPCR)", {"entities": [[39, 53, "TECHNIQUE"], [55, 59, "TECHNIQUE"]]}
" Real Time PCR (Melting Curve Analysis) followed DNA extraction from buccal swabs and statistical analysis of the results was performed", {"entities": [[1, 14, "TECHNIQUE"]]}
" Variants in OPRM1 (A118G), ABCB1 (C3435T), COMT (G472A), OPRD1 (T921C) and ARRB2 (C8622T) genes were tested by real-time PCR", {"entities": [[112, 125, "TECHNIQUE"]]}
" Allelic discrimination was performed by real-time PCR", {"entities": [[41, 54, "TECHNIQUE"]]}
" Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in <i>GATA4</i>, <i>VKORC1</i>, <i>CALU</i> and <i>GGCX</i> genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method", {"entities": [[262, 272, "TECHNIQUE"], [321, 329, "TECHNIQUE"]]}
" PCR and next generation sequencing were used for the analysis", {"entities": [[1, 4, "TECHNIQUE"], [9, 35, "TECHNIQUE"]]}
" Significant pairs were prioritized based on strength of association and <i>in-silico</i> miRNA target prediction analyses to select candidates for validation with qRT-PCR", {"entities": [[164, 171, "TECHNIQUE"]]}
" <i>CYP1A2*1F</i> (163C>A; rs762551); <i>CYP2C9*3</i> (1075A>C; rs1057910); and <i>CYP3A5*3</i> (6986A>G; rs776746) polymorphisms were investigated through real-time PCR using TaqMan probes", {"entities": [[156, 169, "TECHNIQUE"], [176, 189, "TECHNIQUE"]]}
" Eleven variants in the thymidylate synthetase (<i>TYMS</i>), methylenetetrahydrofolate reductase (<i>MTHFR</i>)<i>,</i> dihydrofolate reductase (<i>DHFR</i>), <i>SLC19A1</i> and <i>SLCO1B</i> genes were analyzed in 148 patients, using PCR- and sequencing-based methodology", {"entities": [[236, 239, "TECHNIQUE"]]}
" Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups", {"entities": [[51, 54, "TECHNIQUE"], [59, 73, "TECHNIQUE"]]}
" NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively", {"entities": [[160, 168, "TECHNIQUE"], [173, 190, "TECHNIQUE"]]}
" Genotyping of SOD2 (rs4880), PNPL3 (rs738409) and ABCC1 (rs4148350), CBR1 (rs9024) and ABCG2 (rs2231142) was performed by Tetra-ARMS PCR-based technique to evaluate the genotype-phenotype correlation", {"entities": [[123, 137, "TECHNIQUE"]]}
" The patients were genotyped for <i>CYP3A5</i>*3, <i>CYP3A4</i>*1B, <i>CYP3A4</i>*1G, <i>ABCB1</i> G2677T, and <i>ABCB1</i> C3435T polymorphisms by the PCR-RFLP method", {"entities": [[152, 160, "TECHNIQUE"]]}
" Here, we present two simple novel approaches for the identification of samples carrying either deletions or duplications of the <i>CYP2D6</i> gene; by relative quantification using a singleplex 5'nuclease real-time PCR assay, and by high-resolution melting of PCR products", {"entities": [[184, 225, "TECHNIQUE"]]}
" Drug levels were analyzed using liquid chromatography at different days of therapy, whereas variants in genes encoding transporters and nuclear factors were investigated using real-time PCR", {"entities": [[177, 190, "TECHNIQUE"]]}
" Allelic discrimination analysis was performed using a step one real-time PCR machine", {"entities": [[64, 77, "TECHNIQUE"]]}
" Here, we present a new method for polymerase chain reaction (PCR) melting curve analysis using one fluorescent probe to discriminate the UGT1A1*1 [(TA)<sub>6</sub> ] and *28 [(TA)<sub>7</sub> ] genotypes", {"entities": [[62, 65, "TECHNIQUE"]]}
" Genotypes of 10 SNPs from four different genes were analyzed using the allelic discrimination PCR technique", {"entities": [[95, 98, "TECHNIQUE"]]}
" Genotyping was performed using real-time PCR and long-range PCR", {"entities": [[32, 45, "TECHNIQUE"], [50, 64, "TECHNIQUE"]]}
" Five single-nucleotide polymorphisms were genotyped by real-time PCR assays: prostaglandin-F2\u03b1 receptor (rs3766355, rs3753380); cytochrome-P450 2D6 (rs16947, rs769258); and beta-2-adrenergic receptor (rs1042714)", {"entities": [[57, 69, "TECHNIQUE"]]}
" In this study, we evaluated TaqMan PCR for detection of the NUDT15 single-nucleotide polymorphisms (SNPs) and examined the clinical impact of Arg139His on thiopurine-induced leukopenia", {"entities": [[29, 40, "TECHNIQUE"]]}
" First, we demonstrated that a TaqMan PCR assay successfully detected the Arg139His polymorphism of NUDT15 in clinical samples", {"entities": [[31, 41, "TECHNIQUE"]]}
" Next, the NUDT15 gene polymorphisms (Arg139Cys and Arg139His) were separately analyzed by TaqMan Real-Time PCR in 189 patients from August 2018 to July 2019", {"entities": [[91, 112, "TECHNIQUE"]]}
"719A>G were detected by PCR-restriction fragment length polymorphism assay and c", {"entities": [[24, 68, "TECHNIQUE"]]}
" The expression of 32 target genes in 80 paired specimens (pre-chemotherapeutic primary tumor, post-chemotherapeutic primary tumor and pulmonary metastasis) obtained from 33 patients diagnosed with OS were analyzed by the real-time PCR methodology", {"entities": [[221, 235, "TECHNIQUE"]]}
" Genotyping was performed using PCR-RFLP and direct Sanger sequencing", {"entities": [[32, 40, "TECHNIQUE"], [52, 69, "TECHNIQUE"]]}
" However, an imbalance in the PCR amplification of different haplotypes could affect the accuracy of typing results", {"entities": [[30, 47, "TECHNIQUE"]]}
" <i>IL5RA</i> mRNA expression level was analyzed in different groups of patients by performing qPCR assays", {"entities": [[95, 106, "TECHNIQUE"]]}
" SNPs were analyzed using real-time PCR with TaqMan<sup>\u00ae</sup> probes", {"entities": [[26, 40, "TECHNIQUE"]]}
" <i>Results</i>: Based on the analysis of melt profile data for each PCR product, the identification of polymorphisms was carried out", {"entities": [[69, 72, "TECHNIQUE"]]}
" In this context, there is reported a case in which a routine PCR-SS approach for genotyping <i>DPYD</i> SNP rs55886062 failed in a proband of African descent", {"entities": [[62, 68, "TECHNIQUE"]]}
" The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062", {"entities": [[20, 43, "TECHNIQUE"], [45, 48, "TECHNIQUE"], [124, 127, "TECHNIQUE"]]}
" This preventive measure is essential to avoid sequence frameshifts or primer misalignments arising from SNP occurrences in the genome, which can compromise PCR-SS and lead to genotyping failures", {"entities": [[157, 163, "TECHNIQUE"]]}
" Delivery of proteins and peptides presents special challenges", {"entities": [[1, 34, "CHALLENGE"]]}
" The ideal DDS, commercial aspects, current achievements, challenges, and future prospects are also discussed", {"entities": [[58, 68, "NO_ENTITY"]]}
" With the aim of helping to address some of these challenges, this article discusses the steps that are involved in the development of predictive tests for drug treatment response based on genetic variation, and factors that influence the development and performance of these tests", {"entities": [[36, 60, "NO_ENTITY"]]}
" Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries", {"entities": [[94, 132, "CHALLENGE"], [157, 183, "CHALLENGE"]]}
" However, the challenges for realizing such goals remain substantial", {"entities": [[14, 24, "NO_ENTITY"]]}
" Genomic variation among individuals and populations is a new factor that enriches and challenges our understanding of these complex relationships", {"entities": [[1, 52, "CHALLENGE"]]}
"Variable warfarin response during treatment initiation poses a significant challenge to providing optimal anticoagulation therapy", {"entities": [[0, 26, "CHALLENGE"]]}
" The challenge remains therefore, to develop more effective systemic therapies against this challenging malignancy", {"entities": [[37, 78, "CHALLENGE"]]}
" A within-subjects cross-over medication design was used along with an intravenous alcohol challenge completed after 4 days of both naltrexone and placebo", {"entities": [[71, 100, "NO_ENTITY"]]}
"Despite major advancements in therapeutics, variability in drug response remains a challenge in both adults and children diagnosed with rheumatic disease", {"entities": [[44, 72, "CHALLENGE"]]}
" Additionally, we discuss the major challenges in translating this knowledge into a systems-level understanding of drug physiology, with the ultimate goal of developing more effective personalized clinical treatment strategies", {"entities": [[50, 111, "CHALLENGE"]]}
" Participants were 40 heavy drinkers (12 female) who underwent an intravenous alcohol challenge paradigm after receiving naltrexone (50mg) or placebo in randomized and crossover fashion", {"entities": [[66, 85, "NO_ENTITY"]]}
" This article explains the science behind pharmacogenomics, and describes some of the challenges that have been encountered in the field, with a specific focus on paediatrics", {"entities": [[74, 96, "NO_ENTITY"]]}
"Pregnancy increases the pharmacological management challenge of numerous neurological diseases as a result of complex physiological changes", {"entities": [[24, 50, "NO_ENTITY"]]}
" In this article, we present an overview of the opportunities and challenges that influence the oral health community's full participation in personalized medicine", {"entities": [[66, 76, "NO_ENTITY"]]}
" This article will discuss the issues involved in mobilizing a PGx study during the conduct of a clinical trial, including the development of a PGx hypothesis, the identification of genetic markers for analysis, PGx platform selection and assay development, as well as challenges that arise in relation to global laws and regulations related to genetic research and logistical/timeline concerns in the execution of a PGx analysis", {"entities": [[322, 361, "CHALLENGE"], [306, 317, "CHALLENGE"]]}
" In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union", {"entities": [[281, 303, "CHALLENGE"]]}
"Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies", {"entities": [[0, 19, "CHALLENGE"]]}
" Focusing on the challenges of the incidentalome, the large set of incidental findings potentially generated through genotyping, the paper argues that provisional approaches to managing incidental findings may be implemented if necessary to allow benefits of pharmacogenomic testing to be realized in the clinical setting", {"entities": [[35, 48, "CHALLENGE"]]}
" In this paper, we describe studies being conducted within the eMERGE network to develop best practices for integrating genomic findings into the EHR, and the challenges associated with such work", {"entities": [[108, 149, "CHALLENGE"]]}
"For patients requiring long-term anticoagulation, oral vitamin K antagonists (VKAs) such as warfarin have overwhelming efficacy data and present significant challenges", {"entities": [[128, 132, "NO_ENTITY"]]}
" While such cases may be rare, the clinical/genetic testing community must be aware of the challenges of CYP2D6 testing on the AmpliChip platform and implications regarding accuracy of test results", {"entities": [[105, 145, "CHALLENGE"]]}
" However, the challenge now in using chemotherapy to treat nonsmall-cell lung cancer is to identify more molecular markers predictive of drug sensitivity and determine the optimal drug sequences in order to tailor treatment to each patient", {"entities": [[31, 49, "NO_ENTITY"]]}
" Previous literature has established theoretical models for PGx CDS implementation and discussed a number of anticipated real-world challenges", {"entities": [[121, 142, "NO_ENTITY"]]}
" Anticipated challenges include data storage and management, system integration, physician acceptance, and more", {"entities": [[32, 59, "CHALLENGE"], [61, 79, "CHALLENGE"], [81, 101, "CHALLENGE"]]}
" Second, there was consideration of the particular challenges of dealing with adolescent and young adult cancers, exemplified by bone sarcomas", {"entities": [[65, 112, "NO_ENTITY"]]}
" I\u00a0will also mention some of the existing and potential challenges to achieving these ambitious goals", {"entities": [[33, 55, "NO_ENTITY"]]}
" The next-generation sequencing platforms generate huge amounts of genetic variation data and it remains a challenge to interpret the variations that are identified", {"entities": [[67, 89, "CHALLENGE"]]}
" Inevitably, this leads to increased diagnostic delays and challenges in the interpretation of genetic variants", {"entities": [[77, 111, "CHALLENGE"]]}
" In addition, we provide a list of the top 10 crosscutting opportunities and challenges facing the fields of precision medicine and pharmacogenomics, which have broad applicability independent of the drug class involved", {"entities": [[39, 72, "NO_ENTITY"], [77, 88, "NO_ENTITY"]]}
" To meet these challenges, we present a silicon-based integrated microsystem for the detection of multiple single nucleotide polymorphisms (SNPs) directly from human blood", {"entities": [[1, 25, "NO_ENTITY"]]}
"Nowadays, we are experiencing the big data era with the emerging challenge of single data interpretation", {"entities": [[78, 104, "CHALLENGE"]]}
" Implementation challenges include the limited evidence base available to guide clinical use and the lack of data from diverse populations", {"entities": [[39, 60, "CHALLENGE"]]}
"Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS)", {"entities": [[150, 164, "CHALLENGE"], [12, 38, "NO_ENTITY"], [73, 95, "NO_ENTITY"]]}
" A formidable challenge is successfully integrating pharmacogenomic information into clinical practice", {"entities": [[40, 102, "CHALLENGE"]]}
" However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption", {"entities": [[29, 57, "CHALLENGE"], [59, 85, "CHALLENGE"], [87, 131, "CHALLENGE"], [133, 173, "CHALLENGE"], [179, 267, "CHALLENGE"]]}
" The treatment of depression has been a challenge for a majority of patients and healthcare practitioners", {"entities": [[1, 29, "NO_ENTITY"]]}
" This article describes how LEA and similar analytic frameworks are used internationally, highlights particular challenges with the approach, and proposes ways that LEA might be applied to pharmacogenomic interventions", {"entities": [[112, 122, "NO_ENTITY"]]}
" Herein, we opine on the experience updating the warfarin labeling, highlighting more generally the enabling factors and challenges encountered when considering incorporation of pharmacogenomic information into the prescribing recommendations for already approved drugs", {"entities": [[121, 131, "NO_ENTITY"]]}
" In this study, we challenged primary human osteoblasts, endothelial cells, and neurons derived from induced pluripotent stem cells with specific concentrations of methyl methacrylate (MMA)", {"entities": [[30, 55, "NO_ENTITY"]]}
" This article argues that increased pharmacogenetics education and system-wide implementation is necessary to overcome some of these challenges", {"entities": [[26, 62, "NO_ENTITY"], [67, 93, "NO_ENTITY"]]}
" Here, we discuss the role of sex in zebrafish central nervous system (CNS) models, their molecular mechanisms, recent findings and the existing challenges in this field", {"entities": [[136, 155, "NO_ENTITY"]]}
" However, efficient delivery of this information to the point of prescribing remains a significant challenge", {"entities": [[10, 48, "CHALLENGE"]]}
"The field of pharmacogenomics presents great challenges for researchers that are willing to make their studies reproducible and shareable", {"entities": [[4, 29, "NO_ENTITY"], [30, 55, "NO_ENTITY"]]}
" Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression", {"entities": [[1, 22, "NO_ENTITY"]]}
" Here, we detail successes, challenges, and recent advances in fibrate pharmacogenomics", {"entities": [[63, 87, "NO_ENTITY"]]}
" Here, we provide an overview of considerations made to mitigate multiple methodological challenges that emerged during the design", {"entities": [[65, 88, "NO_ENTITY"]]}
" Potential novel genetic treatment modalities are challenged but still in the early phase of the investigation", {"entities": [[1, 45, "NO_ENTITY"]]}
"The issues and challenges in the diagnosis of drug allergy/hypersensitivity among children and adults in Asia are likely to be different from non-Asian countries", {"entities": [[33, 76, "NO_ENTITY"]]}
"In this response article, we challenge a core assumption that lies at the centre of a round table discussion regarding the Pharmacogenetics to Avoid Loss of Hearing trial", {"entities": [[41, 56, "NO_ENTITY"]]}
" Major challenges to widescale implementation of PGx include lack of physician experience or confidence in interpreting the data", {"entities": [[61, 89, "CHALLENGE"], [93, 128, "CHALLENGE"]]}
" These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy", {"entities": [[26, 89, "CHALLENGE"], [91, 117, "CHALLENGE"], [122, 145, "CHALLENGE"], [155, 195, "CHALLENGE"]]}
" This I-PWG perspective will provide an overview of the steps pharmaceutical companies are taking to address each of these challenges, and the approaches being taken to capitalize on emerging scientific opportunities", {"entities": [[109, 113, "NO_ENTITY"], [143, 165, "NO_ENTITY"]]}
"The development of chronic kidney disease (CKD) drugs remains a challenge due to the variations in the genes", {"entities": [[0, 53, "CHALLENGE"]]}
" However, challenges remain and are hindering the widespread implementation of TDM in clinical practice", {"entities": [[10, 20, "NO_ENTITY"]]}
" The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs", {"entities": [[5, 47, "CHALLENGE"]]}
" Precision medication of psychiatric disorders faces challenges in pharmacogenetics and pharmacodynamics research due to difficulties in recruiting human subjects because of possibility of substance abuse and relatively small sample sizes", {"entities": [[137, 162, "CHALLENGE"]]}
"Despite the introduction of targeted agents leading to therapeutic advances, clinical management of patients with metastatic colorectal cancer (mCRC) is still challenged by significant interindividual variability in treatment outcomes, both in terms of toxicity and therapy efficacy", {"entities": [[173, 234, "CHALLENGE"]]}
" Our editorial explores opportunities and challenges that pharmacogenomics offers for the challenges of polypharmacy and overprescribing of psychotropics in people with intellectual disabilities", {"entities": [[15, 37, "NO_ENTITY"]]}
" These make the management of such patients a challenge", {"entities": [[16, 43, "CHALLENGE"]]}
"The implementation of genotyping for anti-hypertensive drugs in clinical practice remains a challenge", {"entities": [[4, 81, "CHALLENGE"]]}
" This dependence on intracellular activation presents novel challenges for the discovery and development of nucleoside/nucleotide analog drugs", {"entities": [[6, 44, "CHALLENGE"]]}
" To circumvent these challenges, deep neural models are increasingly used to improve the precision and accuracy of warfarin dose predictions", {"entities": [[115, 140, "CHALLENGE"]]}
" However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce", {"entities": [[30, 44, "CHALLENGE"], [65, 98, "CHALLENGE"]]}
" This highlights the university education's crucial role to prepare pharmacists to face future challenges in such a constantly evolving and demanding environment", {"entities": [[95, 105, "NO_ENTITY"]]}
" In recent decades, OS treatment has reached a plateau and drug resistance is still a major challenge", {"entities": [[59, 74, "CHALLENGE"]]}
"Choosing the most effective chemotherapeutic agent with safest side effect profile is a common challenge in\u00a0cancer treatment", {"entities": [[0, 50, "CHALLENGE"]]}
" The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education", {"entities": [[129, 134, "CHALLENGE"], [136, 147, "CHALLENGE"], [153, 162, "CHALLENGE"]]}
"Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges", {"entities": [[0, 48, "CHALLENGE"], [50, 73, "CHALLENGE"], [75, 94, "CHALLENGE"]]}
" There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration", {"entities": [[75, 80, "CHALLENGE"], [82, 107, "CHALLENGE"], [109, 134, "CHALLENGE"], [136, 155, "CHALLENGE"], [157, 188, "CHALLENGE"], [190, 232, "CHALLENGE"]]}
" However, implementing these screening concepts in real-world settings poses challenges", {"entities": [[10, 62, "CHALLENGE"]]}
" Occurring in more than 70 subtypes, sarcomas have broad histological presentations, posing significant challenges of prognosis and treatment", {"entities": [[27, 35, "CHALLENGE"]]}
" The potential applications of these genetic polymorphisms as predictive indicators in clinical practice are explored, as are the challenges associated with their implementation", {"entities": [[163, 177, "CHALLENGE"]]}
"Bortezomib-induced neuropathic pain (BINP) poses a challenge in multiple myeloma (MM) treatment", {"entities": [[0, 35, "CHALLENGE"]]}
" Extensive research has been conducted to address precision medicine challenges using attention mechanism models such as SAN, GAT and transformers", {"entities": [[1, 19, "NO_ENTITY"], [86, 112, "NO_ENTITY"], [121, 124, "NO_ENTITY"], [126, 129, "NO_ENTITY"], [134, 146, "NO_ENTITY"]]}
" Herein, we describe the design of this trial along with challenges encountered during enrollment", {"entities": [[25, 45, "NO_ENTITY"], [87, 97, "NO_ENTITY"]]}
" The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB; www", {"entities": [[26, 57, "DATABASE"]]}
" PharmGKB's website is designed to effectively disseminate knowledge to meet the needs of our users", {"entities": [[1, 9, "DATABASE"]]}
" In order to meet the needs of whole genome studies, PharmGKB has added new functionalities, including browsing the variant display by chromosome and cytogenetic locations, allowing the user to view variants not located within a gene", {"entities": [[53, 61, "DATABASE"]]}
" PharmGKB has also added functionality to accept, store, display and query high throughput SNP array data", {"entities": [[1, 9, "DATABASE"]]}
"The PharmGKB is a publicly available online resource that aims to facilitate understanding how genetic variation contributes to variation in drug response", {"entities": [[4, 12, "DATABASE"]]}
" This unit describes how to navigate the PharmGKB Web site to retrieve detailed information on genes and important variants, as well as their relationship to drugs and diseases", {"entities": [[41, 49, "DATABASE"]]}
" Workflow on how to use PharmGKB to facilitate design of the pharmacogenomic study is also described in this unit", {"entities": [[24, 32, "DATABASE"]]}
" The PharmGKB currently contains information on over 500 drugs, 500 diseases, and 700 genes with genotyped variants", {"entities": [[5, 13, "DATABASE"]]}
"The NIH initiated the PharmGKB in April 2000", {"entities": [[22, 30, "DATABASE"]]}
" PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways", {"entities": [[1, 9, "DATABASE"]]}
" Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small", {"entities": [[89, 124, "DATABASE"], [132, 159, "DATABASE"], [167, 198, "DATABASE"], [214, 222, "DATABASE"]]}
" Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)", {"entities": [[69, 80, "NO_ENTITY"], [266, 271, "DATABASE"], [273, 279, "DATABASE"], [284, 296, "DATABASE"], [149, 157, "DATABASE"], [162, 170, "DATABASE"], [203, 209, "DATABASE"], [230, 236, "DATABASE"]]}
" PharmGKB-based inputs include the following: (i) gene name (HUGO), (ii) drug name and (iii) disease-related keywords", {"entities": [[1, 9, "NO_ENTITY"]]}
"The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project", {"entities": [[4, 37, "DATABASE"], [106, 114, "DATABASE"], [119, 127, "DATABASE"], [181, 195, "DATABASE"]]}
"PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs", {"entities": [[0, 8, "DATABASE"]]}
" PharmGKB contains information about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations on drug-related phenotypes", {"entities": [[1, 9, "DATABASE"]]}
" PharmGKB provides very detailed clinical associations between genetic variants and drug response, including genotype-specific drug dosing guidelines, and this procedure will armGKB", {"entities": [[1, 9, "DATABASE"]]}
" Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations", {"entities": [[78, 84, "DATABASE"], [93, 96, "DATABASE"], [144, 153, "DATABASE"]]}
" We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser", {"entities": [[267, 280, "TECHNIQUE"], [287, 312, "DATABASE"], [321, 360, "DATABASE"], [369, 377, "DATABASE"], [379, 386, "DATABASE"], [419, 454, "DATABASE"], [467, 521, "DATABASE"], [533, 564, "DATABASE"], [577, 607, "DATABASE"], [663, 682, "DATABASE"]]}
" To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB", {"entities": [[117, 125, "TECHNIQUE"]]}
" In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database", {"entities": [[151, 159, "TECHNIQUE"]]}
" MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese", {"entities": [[110, 118, "TECHNIQUE"], [270, 276, "DATABASE"]]}
" The PharmGKB website provides a diverse array of PGx information, from annotations of the primary literature to guidelines for adjusting drug treatment based on genetic information", {"entities": [[5, 13, "DATABASE"]]}
" Coding and regulatory regions of 509 genes, selected from PharmGKB and Phenopedia, were sequenced using massive parallel sequencing in blood DNA from 105 breast cancer patients in the testing phase", {"entities": [[59, 67, "TECHNIQUE"]]}
" Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene", {"entities": [[82, 133, "TECHNIQUE"], [182, 190, "DATABASE"]]}
" Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar", {"entities": [[176, 206, "DATABASE"], [208, 216, "DATABASE"], [222, 229, "DATABASE"]]}
" Furthermore, we identified an additional 61 variants with PharmGKB 2A or 2B clinical annotations", {"entities": [[59, 67, "DATABASE"]]}
" In this study, we genotyped 80 VIP variants from the PharmGKB in 100 members of Blang volunteers from Yunnan province", {"entities": [[54, 62, "DATABASE"]]}
" State-of-the-art knowledge in PGx is mainly available in reference databases such as PharmGKB and reported in scientific biomedical literature", {"entities": [[86, 94, "DATABASE"]]}
" This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)", {"entities": [[196, 204, "DATABASE"], [136, 144, "DATABASE"], [214, 265, "DATABASE"], [267, 271, "DATABASE"]]}
" Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB", {"entities": [[101, 109, "DATABASE"]]}
" A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system", {"entities": [[94, 102, "DATABASE"], [136, 145, "TECHNIQUE"]]}
" Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)", {"entities": [[73, 104, "DATABASE"], [162, 186, "ANALYTICAL_METHOD"]]}
" In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets", {"entities": [[16, 53, "ANALYTICAL_METHOD"], [194, 202, "DATABASE"], [185, 190, "DATABASE"]]}
" Over the last 2\u00a0decades, the Pharmacogenomics Knowledgebase (PharmGKB) has built a unique repository of PGx knowledge, including annotations of clinical guideline and regulator-approved drug labels in addition to evidence-based drug pathways and annotations of the scientific literature", {"entities": [[30, 60, "TECHNIQUE"]]}
" In the first of a series of PharmGKB tutorials, we introduce the PharmGKB coronavirus disease 2019 (COVID-19) portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB", {"entities": [[66, 74, "TECHNIQUE"]]}
" We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB", {"entities": [[172, 180, "TECHNIQUE"]]}
" Filtering the variants according to Pharmacogenomics Knowledge Base (PharmGKB) annotations identified 27 diplotypes and 26 variants with an evident clinical relevance", {"entities": [[37, 68, "TECHNIQUE"]]}
" By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases", {"entities": [[66, 74, "TECHNIQUE"], [79, 87, "TECHNIQUE"], [93, 100, "TECHNIQUE"]]}
" Evidence from the pharmacogenomic literature is curated into PharmGKB as variant annotations, which can be used to create new clinical annotations or added to existing clinical annotations", {"entities": [[62, 70, "TECHNIQUE"]]}
" As more evidence is curated into PharmGKB, the task of maintaining consistency when assessing all the available evidence and assigning an LOE becomes increasingly difficult", {"entities": [[34, 42, "TECHNIQUE"]]}
" In combination with increased standardization of how clinical annotations are written, use of this scoring system helps to ensure that PharmGKB clinical annotations continue to be a robust source of pharmacogenomic information", {"entities": [[136, 144, "TECHNIQUE"]]}
" Based on PharmGKB expert guidelines we identified at least one \"actionable\" variant in all 135 (100%) tested patients", {"entities": [[10, 18, "TECHNIQUE"]]}
" Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test", {"entities": [[42, 66, "TECHNIQUE"], [140, 171, "TECHNIQUE"]]}
" Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB)", {"entities": [[186, 217, "DATABASE"]]}
" Meanwhile, we found several VIP variants that might alter the drug metabolism of cisplatin-cyclophosphamide (CYP2E1), vitamin E (CYP4F2), asthma amlodipine, chlorthalidone, and lisinopril (ACE) through PharmGKB", {"entities": [[202, 211, "DATABASE"]]}
" These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)", {"entities": [[346, 397, "DATABASE"], [408, 438, "DATABASE"]]}
" To evaluate the interest of such pharmacogenetic information, we designed an \"in house\" pipeline to determine the status of 122 PharmGKB (Pharmacogenomics Knowledgebase) variant-drug combinations in 31 genes", {"entities": [[129, 138, "DATABASE"]]}
" We performed a retrospective analysis of drug plasma concentrations and treatment efficacy in patients bearing at least one relevant PharmGKB variant", {"entities": [[134, 142, "DATABASE"]]}
" <b>Materials & methods:</b> We selected 66 VIP variants from PharmGKB (www", {"entities": [[62, 70, "DATABASE"]]}
" Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases", {"entities": [[98, 106, "DATABASE"], [111, 118, "DATABASE"]]}
" Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence", {"entities": [[26, 57, "DATABASE"]]}
", frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases", {"entities": [[178, 185, "DATABASE"]]}
"0% of the individuals carried at least one high risk genotype-predicted phenotype in pharmacogenes with PharmGKB level of evidence 1A for drug interaction", {"entities": [[104, 112, "DATABASE"]]}
"0% of the cohort used at least one PharmGKB evidence level 1A drug, and 18", {"entities": [[35, 43, "DATABASE"]]}
" To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcase<i>CYP2D6</i>, a gene that metabolizes approximately 25% of all prescribed drugs", {"entities": [[160, 168, "DATABASE"]]}
" In this guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants", {"entities": [[109, 117, "DATABASE"]]}
" Here, we used Oxford Nanopore Technologies' adaptive sampling to enrich a panel of 1,036 genes with well-documented PGx relevance extracted from the Pharmacogenomics Knowledge Base (PharmGKB)", {"entities": [[150, 181, "DATABASE"]]}
" We utilized PyPGx to identify star alleles (haplotype patterns) and compared allele frequencies across populations using the Pharmacogenomics Knowledgebase PharmGKB", {"entities": [[157, 165, "DATABASE"]]}
" 54 VIP variants were selected from the Pharmacogenomics Knowledge Base (PharmGKB) and genotyped in 200 Yi individuals", {"entities": [[40, 71, "DATABASE"]]}
" A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided", {"entities": [[57, 65, "DATABASE"], [135, 186, "DATABASE"]]}
" Furthermore, we explored the landscape of DPWG pharmacogenes in gnomAD and our in-house cohort as well as compared bioinformatic tools for WGS-based structural variant detection in <i>CYP2D6</i>", {"entities": [[65, 71, "DATABASE"]]}
" We further assessed the distribution of the identified rare and common pharmacogenomics variants amongst different GnomAD subpopulations", {"entities": [[116, 122, "DATABASE"]]}
" Overall, our findings show that the use of publicly available sequence data, such as the DiscovEHR dataset and GnomAD, provides an opportunity for a deeper understanding of genetic variation in pharmacogenes with direct implications in clinical pharmacogenomics", {"entities": [[90, 99, "DATABASE"]]}
"3% of variants absent from gnomAD database", {"entities": [[27, 33, "DATABASE"]]}
" Here, we analyzed sequence variation data in 141,456 individuals from across eight study populations in gnomAD for 38 CYP genes to identify such variants in addition to common variants", {"entities": [[105, 111, "DATABASE"]]}
" Certain common functional variants including NUDT15 13:48611934 G/A (rs186364861), UGT1A1 2:234676872 C/T (rs34946978), and ALDH2 12:112241766 G/A (rs671) were population-specific for CMDB Chinese because they were absent (with a zero of variant allele frequency) or very rare in other gnomAD populations", {"entities": [[287, 293, "DATABASE"]]}
" Differences in variant allele frequency were observed among the populations studied and the corresponding gnomAD population for 7", {"entities": [[107, 113, "DATABASE"]]}
" Allelic frequencies were compared to other populations reported in the public gnomAD database", {"entities": [[79, 85, "DATABASE"]]}
" We compare our allelic frequencies with these from populations described in the gnomAD database", {"entities": [[81, 87, "DATABASE"]]}
"009, logistic regression), when comparing \"best\" and \"worst\" risk groups", {"entities": [[4, 24, "ANALYTICAL_METHOD"]]}
" Results were assessed by Cox model for survival and by logistic regression for response and toxicity", {"entities": [[26, 35, "ANALYTICAL_METHOD"], [56, 75, "ANALYTICAL_METHOD"]]}
" Logistic regression was applied to assess CYP2C19 polymorphism as an effect modifier of cyclophosphamide", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" These models were evaluated within the PLATO software package using pair wise logistic regression models", {"entities": [[69, 105, "ANALYTICAL_METHOD"]]}
" Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk", {"entities": [[1, 32, "ANALYTICAL_METHOD"]]}
" Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype", {"entities": [[1, 48, "ANALYTICAL_METHOD"]]}
" With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons", {"entities": [[10, 41, "ANALYTICAL_METHOD"], [64, 101, "ANALYTICAL_METHOD"], [113, 132, "ANALYTICAL_METHOD"]]}
" Our data revealed that the MFNN models were superior to the logistic regression model", {"entities": [[28, 39, "ANALYTICAL_METHOD"], [61, 86, "ANALYTICAL_METHOD"]]}
" The factors associated with the decision to test were evaluated using \u03c7(2) and multivariate logistic regression", {"entities": [[70, 75, "ANALYTICAL_METHOD"], [80, 112, "ANALYTICAL_METHOD"]]}
" Our logistic regression analyses indicated the probability that 76% patients carrying combination of four SNPs will not show favorable response to AAP therapy", {"entities": [[5, 24, "ANALYTICAL_METHOD"]]}
" A multiple linear regression model revealed that the ABCC3 -211C/T polymorphism was not independently associated with ADP-induced MPA measurements; a multiple logistic regression model revealed that carrying the ABCC3 -211C allele was not associated with the risk of developing an ST event in clopidogrel-treated patients not harbouring CYP2C19*2, *3 and *17 variants", {"entities": [[3, 29, "ANALYTICAL_METHOD"]]}
" Seven candidate polymorphisms (rs3842 and rs1045642 in ABCB1, rs212091 and rs3743527 in ABCC1, rs3745274 in CYP2B6, rs628031 in SLC22A1 and rs1517618 in SLCO3A1) were evaluated if they were associated with virological failure through logistic regression analysis", {"entities": [[235, 254, "ANALYTICAL_METHOD"]]}
" Logistic regression including appropriate covariates was performed", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
"1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)", {"entities": [[56, 75, "ANALYTICAL_METHOD"], [86, 105, "ANALYTICAL_METHOD"]]}
"6% in the evaluation by means of logistic regression", {"entities": [[33, 52, "ANALYTICAL_METHOD"]]}
" A multivariate analysis by logistic regression confirmed its significant contribution (p = 0", {"entities": [[3, 24, "ANALYTICAL_METHOD"], [28, 47, "ANALYTICAL_METHOD"]]}
" Multivariate logistic regression revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in CTLA4, rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with paradoxical reactions", {"entities": [[1, 33, "ANALYTICAL_METHOD"]]}
" Quality control of genome-wide data was performed according to standard criteria and linear/logistic regression models were used as appropriate under an additive hypothesis", {"entities": [[86, 112, "ANALYTICAL_METHOD"]]}
" Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months", {"entities": [[1, 29, "ANALYTICAL_METHOD"], [34, 48, "ANALYTICAL_METHOD"]]}
" A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death demonstrated a significant trend in multiple logistic regression analysis of CYP2C19 variants, with lower odds of secondary endpoint in patients carrying at least 1 LOF allele (*2, *3, *8) than in wild-type homozygotes (OR 0", {"entities": [[128, 147, "ANALYTICAL_METHOD"]]}
" Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Logistic regression was used to test for association between these polymorphisms and treatment response", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Multivariate logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR", {"entities": [[1, 33, "ANALYTICAL_METHOD"]]}
" In a binary logistic regression analysis the odds ratio (OR) was 8", {"entities": [[6, 32, "ANALYTICAL_METHOD"]]}
" Association with toxicities was evaluated retrospectively using logistic regression analysis", {"entities": [[65, 84, "ANALYTICAL_METHOD"]]}
" A non-conditional logistic regression was used to identify the factors associated with hepatotoxicity", {"entities": [[3, 38, "ANALYTICAL_METHOD"]]}
" Multivariate logistic regression analysis was used to structure a nomogram", {"entities": [[1, 33, "ANALYTICAL_METHOD"]]}
" Univariate and multivariate statistical analysis by logistic regression revealed 10 SNPs associated with severe adverse reactions to capecitabine (P<0", {"entities": [[53, 72, "ANALYTICAL_METHOD"]]}
" The relation of SOCS1-1478 CA/del polymorphism to PCOS status and insulin resistance was analysed via logistic regression analysis", {"entities": [[103, 122, "ANALYTICAL_METHOD"]]}
" Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity", {"entities": [[74, 106, "ANALYTICAL_METHOD"]]}
" The genetic associations were tested using logistic regression analyses", {"entities": [[44, 63, "ANALYTICAL_METHOD"]]}
" Logistic regression analysis showed that the dose of metoprolol and the genotypes of <i>CYP2D6</i> were predictors of heart rate\u00a0<70\u00a0beats/min in these patients", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression", {"entities": [[1, 18, "ANALYTICAL_METHOD"], [119, 161, "ANALYTICAL_METHOD"]]}
" Next, binary logistic regression was applied to evaluate the association of the PGSs to SSRIs treatment response in a discovery sample (ISPC, N\u2009=\u2009865), and in a replication cohort (STAR*D, N\u2009=\u20091,878)", {"entities": [[7, 33, "ANALYTICAL_METHOD"]]}
"<b>Conclusions:</b> This study did identify associations between <i>CHRM2</i> variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors", {"entities": [[112, 131, "ANALYTICAL_METHOD"]]}
"2) and clinical conditions in relation to severe (III-IV) adverse drug reactions (ADRs), stepwise forward multivariate logistic regression analyses were performed", {"entities": [[119, 138, "ANALYTICAL_METHOD"]]}
" Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the <i>SLC22A1</i>, <i>SLC22A2</i>, and <i>SLC22A3</i> genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (<i>p</i> < 0", {"entities": [[27, 46, "ANALYTICAL_METHOD"]]}
" Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively", {"entities": [[1, 24, "ANALYTICAL_METHOD"], [29, 48, "ANALYTICAL_METHOD"]]}
" The three top scoring SNPs (rs12248560, rs878567, rs17710780) were subsequently combined into an unweighted GRS, which was included in linear and logistic regression models using the CES-D score, occurrence of a major depressive episode (MDE) during follow-up and regular antidepressant treatment during the 6 months preceding follow-up assessment as outcomes", {"entities": [[147, 166, "ANALYTICAL_METHOD"]]}
" Linear and logistic regression analyses were used to assess predictors of withdrawal symptomatology", {"entities": [[12, 31, "ANALYTICAL_METHOD"]]}
" Logistic regression analysis showed that high SAMe-TT<sub>2</sub>R<sub>2</sub> score was the only statistically significant predicting factor of poor INR control (odds ratio (OR) 5", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Cox and logistic regression models with Elastic net penalty were employed", {"entities": [[1, 4, "ANALYTICAL_METHOD"], [9, 28, "ANALYTICAL_METHOD"]]}
" In a logistic regression analysis, higher CYP2C19 activity (OR (95% CI): 4", {"entities": [[6, 25, "ANALYTICAL_METHOD"]]}
" We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)", {"entities": [[16, 32, "ANALYTICAL_METHOD"], [55, 77, "ANALYTICAL_METHOD"], [84, 106, "ANALYTICAL_METHOD"], [114, 136, "ANALYTICAL_METHOD"], [145, 164, "ANALYTICAL_METHOD"], [171, 187, "ANALYTICAL_METHOD"], [195, 235, "ANALYTICAL_METHOD"], [244, 267, "ANALYTICAL_METHOD"], [278, 297, "ANALYTICAL_METHOD"]]}
" We used a logistic regression model to identify patient variables that predicted successful enrollment after subjects were contacted and evaluated the reasons that clinical trial eligible subjects refused enrollment", {"entities": [[11, 30, "ANALYTICAL_METHOD"]]}
" Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ", {"entities": [[1, 34, "ANALYTICAL_METHOD"]]}
" Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments", {"entities": [[167, 172, "ANALYTICAL_METHOD"], [177, 196, "ANALYTICAL_METHOD"]]}
" The association between genotypes, alleles and blood pressure response to treatment was determined by conducting multivariate logistic regression model analysis", {"entities": [[114, 146, "ANALYTICAL_METHOD"]]}
" <b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively", {"entities": [[189, 208, "ANALYTICAL_METHOD"], [213, 248, "ANALYTICAL_METHOD"]]}
" In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)", {"entities": [[177, 196, "ANALYTICAL_METHOD"], [207, 226, "ANALYTICAL_METHOD"]]}
" We genotyped 16 polymorphisms in genes for enzymes involved in the folate-methionine pathway and in methotrexate transport, and analysed their association with treatment efficacy and toxicity using classification and regression tree analysis and logistic regression", {"entities": [[247, 266, "ANALYTICAL_METHOD"]]}
" We constructed the predictive model using logistic regression", {"entities": [[43, 62, "ANALYTICAL_METHOD"]]}
" Multiple logistic regression was then performed to identify the factors associated with rapid CKD progression", {"entities": [[1, 29, "ANALYTICAL_METHOD"]]}
" Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression", {"entities": [[165, 185, "ANALYTICAL_METHOD"], [203, 235, "ANALYTICAL_METHOD"]]}
" Logistic regressions were performed between PRSs and non-response or non-remission in six European clinical samples, adjusting for age, sex, baseline symptom severity, recruitment sites, and population stratification", {"entities": [[1, 21, "ANALYTICAL_METHOD"]]}
" Multivariable logistic regression analyzed the association between one or more gene-x-drug interactions with 90-day readmission", {"entities": [[1, 34, "ANALYTICAL_METHOD"]]}
" Responses were assessed using multivariable logistic regression", {"entities": [[31, 64, "ANALYTICAL_METHOD"]]}
" Logistic regression was used for analysis", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" Multivariable logistic regression analysis was employed to investigate the independent risk factors for bleeding and to develop a risk scoring system", {"entities": [[1, 34, "ANALYTICAL_METHOD"]]}
" Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes", {"entities": [[13, 32, "ANALYTICAL_METHOD"], [82, 103, "ANALYTICAL_METHOD"]]}
" Logistic regression model was used to analyze the correlation between the <i>CYP2D6</i> phenotype and incidence of adverse events, which were assessed over a 12-week period", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" In logistic regression model, the overall incidence of adverse events was 1", {"entities": [[4, 23, "ANALYTICAL_METHOD"]]}
" Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model", {"entities": [[80, 113, "ANALYTICAL_METHOD"]]}
" Two logistic regression models accounted for two diplotypes in OCT1 and ABCB1, including statistically significant covariates", {"entities": [[5, 24, "ANALYTICAL_METHOD"]]}
" Our multinomial logistic regression results may benefit future predictive analyses in diabetic populations", {"entities": [[5, 37, "ANALYTICAL_METHOD"]]}
" Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of <i>ABCC4</i> gene as predisposing factors of RTD", {"entities": [[1, 31, "ANALYTICAL_METHOD"]]}
" Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression", {"entities": [[61, 80, "ANALYTICAL_METHOD"], [85, 108, "ANALYTICAL_METHOD"]]}
" Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR)\u2005=\u20051", {"entities": [[1, 29, "ANALYTICAL_METHOD"]]}
" Negative binomial regression and logistic regression were used", {"entities": [[1, 29, "ANALYTICAL_METHOD"], [34, 53, "ANALYTICAL_METHOD"]]}
" Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model", {"entities": [[80, 113, "ANALYTICAL_METHOD"]]}
" Logistic regression models were fitted to assess the impact of activity scores on symptom improvement and side effects", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" We conducted logistic regression models to examine the association of genetic variants with CAA/L during acute KD and with persistence >6 weeks using an additive model between cases and 238 controls with no CAA", {"entities": [[14, 33, "ANALYTICAL_METHOD"]]}
" Genetic association analyses were conducted using the additive model and multivariable logistic regression", {"entities": [[1, 20, "ANALYTICAL_METHOD"], [55, 69, "ANALYTICAL_METHOD"], [74, 107, "ANALYTICAL_METHOD"]]}
" The Japonica array provides better imputation performance for Japanese individuals than the existing commercially available SNP arrays with both the 1KJPN panel and the International 1000 genomes project panel", {"entities": [[184, 205, "NO_ENTITY"]]}
" We demonstrate ePGA's functionality on genetic variation data from the 1000 Genomes Project", {"entities": [[72, 92, "DATABASE"]]}
" The 1000 Genomes Project data were analyzed to describe population genetic variation and statistics for these five genes in self-reported healthy individuals in five global super- and 26 sub-populations", {"entities": [[5, 25, "DATABASE"]]}
" By contrast, ABCC8 rs1799854 genomic and allelic frequencies among MM were observed to be significantly different from those reported by the 1000 Genomes Project, and from diabetic patients within other populations reported in the literature, such as the European, Asian and Latin-American individuals [T=0", {"entities": [[142, 162, "NO_ENTITY"]]}
" Herein, we exploit ePGA, a web-based electronic Pharmacogenomics Assistant and publicly available genetic data from the 1000 Genomes Project to explore genotype to phenotype associations among the 1000 Genomes Project populations", {"entities": [[121, 141, "DATABASE"]]}
" This study aims to identify and characterize likely causal variants within well-established pharmacogenomic genes using next-generation sequencing data from the 1000 Genomes Project", {"entities": [[162, 182, "DATABASE"]]}
" We identified common Neanderthal variants in lymphoblastoid cell lines (LCLs) derived from the globally diverse 1000 Genomes Project and Caucasian cell lines from the Children's Hospital of Oakland Research Institute", {"entities": [[113, 133, "NO_ENTITY"]]}
"77 M small indels, identified from 991 Chinese individuals of the Chinese Academy of Sciences Precision Medicine Initiative Project (CASPMI) and 301 Chinese individuals of the 1000 Genomes Project (1KGP)", {"entities": [[176, 196, "DATABASE"]]}
" This study aimed to identify the distribution differences of very important pharmacogene (VIP) variants between the Tibetan population and the other 26 populations from the 1000 Genomes project", {"entities": [[174, 194, "DATABASE"]]}
" To test potential associations between noncoding and coding pharmacogenetic variants, we computed a drug-level GVB for 5099 drugs from DrugBank for 2504 genomes of the 1000 Genomes Project and evaluated the correlation between the long-known noncoding variant-drug associations in PharmGKB, with functionally relevant rare and common coding variants aggregated into GVBs", {"entities": [[169, 189, "DATABASE"]]}
" The apparent discrepancy with our previous results for NUDT15 rs116855232 in the Ad Mixed American superpopulation of the 1000 Genomes Project is ascribed to the diversity of the Native populations of the Americas", {"entities": [[123, 143, "DATABASE"]]}
" Among the accuracy controls were 32 samples from the 1000 Genomes Project that were selected based on their enrichment of sequence variants included in the pharmacogenetic panel (VarCover", {"entities": [[54, 74, "DATABASE"]]}
" Frequency of CYP2C19*2, *3 and *17 alleles were obtained from 1000 Genomes project Phase III in line with Fort Lauderdale principles", {"entities": [[63, 83, "DATABASE"]]}
" In this study, we analyzed the whole-genome sequencing data from The 1000 Genomes Project (Phase 3) and the pharmacogenetic information from Drug Bank, PharmGKB, PharmaADME, and Biotransformation", {"entities": [[70, 90, "DATABASE"]]}
"1 was used to infer haplotypes and diplotypes of six GSTA1 promoter SNPs on 2501 individuals from 26 populations classified by the 1000 Genomes Project into five super-populations that included Africa (N\u2009=\u2009660), America (N\u2009=\u2009347), East Asia (N\u2009=\u2009504), Europe (N\u2009=\u2009502), and South Asia (N\u2009=\u2009488)", {"entities": [[131, 151, "NO_ENTITY"]]}
" Whole genome sequencing data from the 1000 Genomes Project and the African Genome Variation Project were mined to assess variation in <i>DPYD</i> in eight sub-Saharan African populations", {"entities": [[39, 59, "DATABASE"]]}
" \u03c7<sup>2</sup> test was used to evaluate the significant differences of genotype and allele frequencies between the Li and the other 13 populations from 1000 Genomes Project", {"entities": [[153, 173, "DATABASE"]]}
" In contrast, long-read HiFi sequencing phased all variants across the NUDT15 amplicons, including a *2/*9 diplotype that previously was characterized as *1/*2 in the 1000 Genomes Project v3 data set", {"entities": [[167, 187, "DATABASE"]]}
" This let us to compare the frequency of gene variants involved in response to drugs among our population and others, taking data from the 1000 Genomes Project", {"entities": [[139, 159, "DATABASE"]]}
" The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the \u03c7<sup>2</sup> test", {"entities": [[75, 95, "DATABASE"]]}
" <b>Results:</b> Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy\u00a0and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population", {"entities": [[49, 69, "DATABASE"]]}
" These assessments encompass reference materials from the Genome-In-A-Bottle (GIAB), the Genetic Testing Reference Material Coordination Program (GeT-RM) projects, as well as additional samples from the 1000 Genomes project (1KGP)", {"entities": [[203, 223, "DATABASE"]]}
" The allele frequencies and genotype distribution data of 26 populations were obtained from the 1000 Genomes Project, followed by a comparison and statistical analysis", {"entities": [[96, 116, "DATABASE"]]}
" We developed a new method to construct haplogroups, representing a common ancestry structure, by iteratively excluding rare and functional variants of the 25 representative pharmacogenes using the 2504 genomes from the 1000 Genomes Project", {"entities": [[220, 240, "DATABASE"]]}
" For another pharmacogenetic hurdle, the speed by which a pharmacogenetic profile for a certain drug can be obtained in an individual patient, there has been a revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a large number of genes up to the complete genome in a single reaction", {"entities": [[221, 247, "TECHNIQUE"]]}
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \"post-genomic era\"", {"entities": [[40, 50, "TECHNIQUE"], [67, 97, "TECHNIQUE"], [122, 148, "TECHNIQUE"]]}
" However, with the rise of new technologies, as next generation sequencing, allowing to obtain pre-emptive genetic information, one must be aware that the question will no longer be whether to genotype or not but rather whether or not to use the information already there", {"entities": [[48, 74, "TECHNIQUE"]]}
"org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments", {"entities": [[196, 222, "TECHNIQUE"], [230, 236, "TECHNIQUE"], [242, 252, "TECHNIQUE"]]}
" Results from the initial next generation sequencing studies indicate an enrichment of rare variants in pathways and genes that were previously found to be associated with BD", {"entities": [[26, 52, "TECHNIQUE"]]}
" Furthermore, the development of next generation sequencing technology and non-invasive approaches to analyze circulating tumor DNA will make real-time monitoring of the tumor pharmacogenomic markers possible in the clinical routine, rendering precision medicine available to every patient", {"entities": [[33, 59, "TECHNIQUE"]]}
" In the current study, the mRNA and microRNA (miRNA) expression profiles derived from next generation sequencing data for APAP-treated (5 and 10\u00a0mM) HepaRG cells and controls were analyzed systematically", {"entities": [[86, 112, "TECHNIQUE"]]}
"With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples", {"entities": [[24, 50, "TECHNIQUE"]]}
" To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective", {"entities": [[117, 143, "TECHNIQUE"], [151, 182, "ANALYTICAL_METHOD"], [191, 208, "TECHNIQUE"], [212, 223, "TECHNIQUE"]]}
" Recent progress in Next Generation Sequencing (NGS) technologies has for the first time allowed to comprehensively map the genetic landscape of human pharmacogenes", {"entities": [[20, 46, "TECHNIQUE"]]}
"Extraordinary advances in high throughput next generation sequencing (NGS) technology and bioinformatics are the main thrust that transforms the current state of healthcare into the era of precision medicine where clinical practice takes individual variability into account", {"entities": [[42, 68, "TECHNIQUE"]]}
" The manuscripts in following categories are welcome, but not limited to: Application of next generation sequencing in clinical diagnosis, including but not limited to rare genetic disease, complex inherited disease, prenatal/perinatal screening, oncology, organ transplantation and pathogen identification; Novel bioinformatics approaches in human genomics; Single cell sequencing, liquid biopsy and other emerging genomic assays in molecular genetics, pharmacogenomics, oncology and immuno-oncology; Integration of genomics with other \"omics\" technology in genetic medicine", {"entities": [[89, 115, "TECHNIQUE"]]}
"High-throughput next generation sequencing (NGS) is a shotgun approach applied in a parallel fashion by which the genome is fragmented and sequenced through small pieces and then analyzed either by aligning to a known reference genome or by de novo assembly without reference genome", {"entities": [[16, 42, "TECHNIQUE"]]}
" Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)", {"entities": [[1, 27, "TECHNIQUE"], [223, 274, "DATABASE"], [290, 326, "DATABASE"]]}
" It also plays a fundamental role in nucleic acid sequencing applications, including Next Generation Sequencing (NGS)-based ones", {"entities": [[85, 111, "TECHNIQUE"]]}
" PCR and next generation sequencing were used for the analysis", {"entities": [[1, 4, "TECHNIQUE"], [9, 35, "TECHNIQUE"]]}
" In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium", {"entities": [[23, 49, "TECHNIQUE"], [61, 89, "TECHNIQUE"]]}
"For the advances of pediatric oncology next generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed", {"entities": [[39, 65, "TECHNIQUE"]]}
"The rapid clinical implementation of next generation sequencing techniques\u00a0is\u00a0 due to its ability to sequence a large number of genetic regions at\u00a0lower costs\u00a0 than conventional techniques", {"entities": [[37, 63, "TECHNIQUE"]]}
" Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing", {"entities": [[41, 44, "TECHNIQUE"], [46, 55, "TECHNIQUE"], [61, 96, "TECHNIQUE"]]}
" Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq\u2122 panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes", {"entities": [[56, 82, "TECHNIQUE"]]}
" <b>Conclusion:</b> The implementation of Precision Medicine by using tools such as Next Generation Sequencing and TDM led to diagnose and select a targeted therapy for the treatment of a KCNT1-related epilepsy in a patient presented with EIMFS in early infancy and poor response to antiepileptic drugs", {"entities": [[84, 110, "TECHNIQUE"]]}
"The increasing availability of next generation sequencing (NGS) for personal genomics could promote pharmacogenomics (PGx) discovery and application", {"entities": [[31, 57, "TECHNIQUE"]]}
" Nowadays, a plethora of studies implement next generation sequencing to capture rare and novel pharmacogenomic (PGx) variants that influence drug response", {"entities": [[43, 69, "TECHNIQUE"]]}
" To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations", {"entities": [[207, 210, "TECHNIQUE"], [212, 238, "TECHNIQUE"]]}
" An innovative multimodal targeted next generation sequencing (mmNGS) approach with custom primers designed for the most commonly reported SNPs of genes belonging to DNA repair, CDDP transport or detoxification, or associated with CDPP-related toxicity was applied", {"entities": [[26, 61, "TECHNIQUE"]]}
" Massively parallel, next generation sequencing (NGS), has allowed pharmacogenetics to be subsumed by pharmacogenomics with respect to the identification of variants associated with responders and non-responders, optimal drug response, and adverse drug reactions", {"entities": [[21, 47, "TECHNIQUE"]]}
" It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text", {"entities": [[70, 86, "ANALYTICAL_METHOD"], [90, 128, "ANALYTICAL_METHOD"]]}
" In this literature-based study, we compared the performances of eight machine learning techniques with those of MLR in a large, racially-diverse cohort", {"entities": [[71, 87, "ANALYTICAL_METHOD"]]}
"We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background", {"entities": [[62, 78, "ANALYTICAL_METHOD"]]}
" Very recently, machine learning regression has been used to investigate how well cancer cell line sensitivity to drugs is predicted depending on the type of molecular profile", {"entities": [[16, 43, "ANALYTICAL_METHOD"]]}
" R code to facilitate the construction of alternative machine learning models and their validation in the presented benchmark is available at http://ballester", {"entities": [[54, 70, "ANALYTICAL_METHOD"]]}
" With machine learning and integrated pharmacogenomics and metabolomics, we demonstrate that KA efficacy is not determined by the status of individual genes, but by the quantitative extent of the WE, leading to a therapeutic window in\u00a0vivo", {"entities": [[6, 22, "ANALYTICAL_METHOD"]]}
" Machine learning models showed that independent SNPs in this pathway predicted TRD with a mean sensitivity of 0", {"entities": [[1, 17, "ANALYTICAL_METHOD"]]}
" Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine", {"entities": [[1, 15, "ANALYTICAL_METHOD"], [40, 56, "ANALYTICAL_METHOD"]]}
" Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers", {"entities": [[12, 29, "CHALLENGE"], [31, 41, "CHALLENGE"], [43, 56, "CHALLENGE"], [62, 146, "CHALLENGE"], [148, 164, "ANALYTICAL_METHOD"]]}
" Among the identified small set of genes associated with reduced breast cancer incidence, laboratory experiments on one of the genes, CDC42, showed that its downregulation by metformin inhibited cancer cell migration and proliferation, thus validating the ability of machine learning approaches to identify biologically relevant candidates for laboratory experiments", {"entities": [[267, 283, "ANALYTICAL_METHOD"]]}
"During the last decade, the interest to apply machine learning algorithms to genomic data has increased in many bioinformatics applications", {"entities": [[46, 62, "ANALYTICAL_METHOD"]]}
" Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone", {"entities": [[1, 28, "ANALYTICAL_METHOD"], [33, 50, "ANALYTICAL_METHOD"]]}
" Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R", {"entities": [[63, 76, "ANALYTICAL_METHOD"], [128, 141, "ANALYTICAL_METHOD"], [146, 159, "ANALYTICAL_METHOD"]]}
" This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project", {"entities": [[151, 174, "ANALYTICAL_METHOD"], [179, 195, "ANALYTICAL_METHOD"]]}
"We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD)", {"entities": [[32, 48, "ANALYTICAL_METHOD"]]}
" These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers", {"entities": [[32, 48, "ANALYTICAL_METHOD"]]}
" Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning", {"entities": [[162, 185, "ANALYTICAL_METHOD"], [190, 206, "ANALYTICAL_METHOD"]]}
" We demonstrate that deep neural networks outperform the current state in machine learning frameworks", {"entities": [[21, 41, "ANALYTICAL_METHOD"], [74, 90, "ANALYTICAL_METHOD"]]}
" In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses", {"entities": [[183, 216, "ANALYTICAL_METHOD"], [224, 246, "ANALYTICAL_METHOD"]]}
" A way to generate predictive models for the remaining cases is with suitable machine learning algorithms that are yet to be applied to existing in vitro pharmacogenomics datasets", {"entities": [[78, 94, "ANALYTICAL_METHOD"]]}
" We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)", {"entities": [[16, 32, "ANALYTICAL_METHOD"], [55, 66, "ANALYTICAL_METHOD"], [84, 106, "ANALYTICAL_METHOD"], [114, 136, "ANALYTICAL_METHOD"], [145, 164, "ANALYTICAL_METHOD"], [171, 187, "ANALYTICAL_METHOD"], [195, 235, "ANALYTICAL_METHOD"], [244, 267, "ANALYTICAL_METHOD"], [278, 291, "ANALYTICAL_METHOD"]]}
"The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary", {"entities": [[182, 198, "ANALYTICAL_METHOD"]]}
"In the wake of recent advances in machine learning research, the study of pharmacogenomics using predictive algorithms serves as a new paradigmatic application", {"entities": [[34, 50, "ANALYTICAL_METHOD"]]}
" In this work, our goal was to explore an ensemble machine learning approach which aims to predict probable antidepressant treatment response and remission in major depressive disorder (MDD)", {"entities": [[42, 67, "ANALYTICAL_METHOD"]]}
" We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4", {"entities": [[31, 47, "ANALYTICAL_METHOD"], [103, 142, "ANALYTICAL_METHOD"]]}
" Many machine learning techniques have been demonstrated in this domain", {"entities": [[6, 22, "ANALYTICAL_METHOD"]]}
" Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning", {"entities": [[228, 239, "ANALYTICAL_METHOD"], [244, 260, "ANALYTICAL_METHOD"]]}
" Furthermore, we performed a machine learning analysis and determined that Native American admixture and heart failure were strongly predictive of AF in PHR", {"entities": [[29, 45, "ANALYTICAL_METHOD"]]}
" Here, we leverage publicly available, whole genome sequencing data collected from global populations, evolutionary characteristics, and annotated protein features to construct a new in silico machine learning pharmacogenetic identification method called XGB-PGX", {"entities": [[193, 209, "ANALYTICAL_METHOD"]]}
" We used the anti-epileptic drug brivaracetam as a case study and combine a hybrid data/knowledge-driven feature extraction with machine learning to systematically integrate clinical and genetic data from a clinical discovery dataset (n\u2009=\u2009235 patients)", {"entities": [[129, 145, "ANALYTICAL_METHOD"]]}
" Hence, it provides a blueprint for how machine learning-based multimodal data integration can act as a driver in achieving the goals of precision medicine in fields such as neurology", {"entities": [[40, 56, "ANALYTICAL_METHOD"]]}
" Five machine learning algorithms combined with four resampling techniques were used to build optimal predictive model", {"entities": [[6, 22, "ANALYTICAL_METHOD"]]}
" By machine learning, we have developed and validated comprehensive models to predict the risk of neutropenia and fever", {"entities": [[4, 20, "ANALYTICAL_METHOD"]]}
" This study assesses the value of potentially functional single nucleotide polymorphisms (pfSNPs) and employs six machine learning algorithms to identify the combination of SNPs that best predict myalgia", {"entities": [[114, 130, "ANALYTICAL_METHOD"]]}
" Variants that were highly associated with myalgia from this and previous studies were extracted, assessed for potential functionality (pfSNPs) and incorporated into six machine learning models", {"entities": [[170, 186, "ANALYTICAL_METHOD"]]}
" The minimum combination of SNPs to achieve maximum sensitivity and specificity as determined by AUC, that predict atorvastatin-induced myalgia in most, if not all the six machine learning models was determined", {"entities": [[172, 188, "ANALYTICAL_METHOD"]]}
" pfSNPs were found to be more robust in predicting myalgia, outperforming non-pf SNPs in the majority of machine learning models tested", {"entities": [[105, 121, "ANALYTICAL_METHOD"]]}
" <b>Conclusion:</b> Combinations of pfSNPs that were consistently identified by different machine learning models to have high predictive performance have good potential to be clinically useful for predicting atorvastatin-induced myalgia once validated against an independent cohort of patients", {"entities": [[90, 106, "ANALYTICAL_METHOD"]]}
" This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information", {"entities": [[22, 38, "ANALYTICAL_METHOD"]]}
" Graph structures have received increasing attention owing to their outstanding performance in machine learning", {"entities": [[95, 111, "ANALYTICAL_METHOD"]]}
"This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning", {"entities": [[177, 193, "ANALYTICAL_METHOD"]]}
" Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5", {"entities": [[35, 54, "ANALYTICAL_METHOD"], [6, 22, "ANALYTICAL_METHOD"], [59, 75, "ANALYTICAL_METHOD"], [77, 88, "ANALYTICAL_METHOD"], [90, 104, "ANALYTICAL_METHOD"], [114, 127, "ANALYTICAL_METHOD"], [129, 131, "ANALYTICAL_METHOD"]]}
" When developed machine learning models were evaluated in the validation dataset, the C5", {"entities": [[16, 32, "ANALYTICAL_METHOD"]]}
" In addition, we preliminarily explored the machine learning-based methods for identifying mutation markers of anti-cancer drug sensitivity and produced optimistic results, which suggests that a reliable dataset may provide new insights and essential clues for future cancer pharmacogenomics studies", {"entities": [[44, 60, "ANALYTICAL_METHOD"]]}
" Machine learning methods have been employed to predict drug sensitivity based on the multiple omics data available for large panels of cancer cell lines", {"entities": [[1, 17, "ANALYTICAL_METHOD"]]}
" However, there are no comprehensive guidelines on how to properly train and validate such machine learning models for drug sensitivity prediction", {"entities": [[91, 107, "ANALYTICAL_METHOD"]]}
" However, there is no evidence that machine learning approaches combining multi-omics measures (e", {"entities": [[36, 52, "ANALYTICAL_METHOD"]]}
" Machine Learning (ML) is emerging as a particularly promising complementary approach to precision oncology", {"entities": [[1, 17, "ANALYTICAL_METHOD"]]}
" We compare the accuracy of stable warfarin dose prediction using linear and nonlinear machine learning models in a large cohort enriched for US Latinos and Latin Americans (ULLA)", {"entities": [[77, 103, "ANALYTICAL_METHOD"]]}
" Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%", {"entities": [[26, 74, "ANALYTICAL_METHOD"]]}
" To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics", {"entities": [[141, 157, "ANALYTICAL_METHOD"]]}
" Using machine learning (ML) techniques with pharmacogenomics data provides one pathway toward individualized prediction of therapeutic outcomes of antidepressants", {"entities": [[7, 23, "ANALYTICAL_METHOD"]]}
"Extensive in vitro cancer drug screening datasets have enabled scientists to identify biomarkers and develop machine learning models for predicting drug sensitivity", {"entities": [[109, 125, "ANALYTICAL_METHOD"]]}
" CREAMMIST provides easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for experiments, and training robust machine learning models", {"entities": [[224, 240, "ANALYTICAL_METHOD"]]}
" To overcome this hurdle, machine learning models have been extensively adapted in drug dose prediction", {"entities": [[26, 42, "ANALYTICAL_METHOD"]]}
" The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge", {"entities": [[49, 65, "ANALYTICAL_METHOD"], [78, 89, "ANALYTICAL_METHOD"], [91, 96, "ANALYTICAL_METHOD"], [102, 107, "ANALYTICAL_METHOD"]]}
" Nevertheless, genome-wide expression signatures are still limited in real clinical utility because of insufficient data utilization, a lack of critical validation, and inapposite machine learning algorithms", {"entities": [[180, 196, "NO_ENTITY"]]}
" Based on the concept of precision pharmacy, we adpoted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children and elderly patients", {"entities": [[153, 169, "ANALYTICAL_METHOD"]]}
" The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN", {"entities": [[32, 39, "ANALYTICAL_METHOD"], [44, 66, "ANALYTICAL_METHOD"], [134, 150, "ANALYTICAL_METHOD"], [173, 191, "ANALYTICAL_METHOD"], [210, 252, "ANALYTICAL_METHOD"], [256, 260, "ANALYTICAL_METHOD"]]}
" Machine learning (ML) has been predominantly applied for prediction, despite the advent of deep learning (DL)", {"entities": [[1, 17, "ANALYTICAL_METHOD"], [92, 105, "NO_ENTITY"]]}
" Based on these findings, data from patients treated with cannabis and genotyped for several candidate polymorphic genes (single-nucleotide polymorphism: SNP) were collected, integrated, and analyzed through a machine learning (ML) model to demonstrate that the reduction in pain intensity is closely related to gene polymorphisms", {"entities": [[210, 226, "ANALYTICAL_METHOD"]]}
" Genome-wide patterns of pharmacogenomic variation-6311 drug response-associated variants for <i>All of Us</i> and 5966 variants for <i>UKB</i>-were analyzed with machine learning classifiers to predict participants' self-identified race and ethnicity", {"entities": [[163, 179, "ANALYTICAL_METHOD"]]}
" Based on the concept of precision pharmacy, we adopted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children, and elderly patients", {"entities": [[153, 169, "ANALYTICAL_METHOD"]]}
" A machine learning classifier method was used to discover classification rules for our dataset", {"entities": [[3, 19, "ANALYTICAL_METHOD"]]}
" Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties", {"entities": [[25, 41, "NO_ENTITY"], [69, 85, "CHALLENGE"]]}
" PANCDR outperformed other machine learning models in predicting external test data", {"entities": [[1, 7, "ANALYTICAL_METHOD"], [27, 43, "ANALYTICAL_METHOD"]]}
" Data science and machine learning play a crucial role in the processing and interpretation of results, using enormous databases and statistics to discover new and support current genotype-phenotype correlations", {"entities": [[18, 34, "ANALYTICAL_METHOD"]]}
" A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP", {"entities": [[3, 19, "ANALYTICAL_METHOD"], [189, 195, "DATABASE"], [200, 207, "DATABASE"]]}
" An area of recent interest is the potential for machine learning (ML) applications within pharmacology", {"entities": [[49, 65, "ANALYTICAL_METHOD"]]}
" Two signatures for prognosis and EGFRi sensitivity were developed via machine learning", {"entities": [[71, 87, "ANALYTICAL_METHOD"]]}
" This study investigates how artificial intelligence (AI) and machine learning (ML) can address key challenges in integrating pharmacogenomics (PGx) into psychiatric care", {"entities": [[62, 78, "ANALYTICAL_METHOD"]]}
" The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye", {"entities": [[5, 37, "CHALLENGE"], [42, 57, "CHALLENGE"], [65, 80, "CHALLENGE"], [85, 91, "CHALLENGE"]]}
" However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research", {"entities": [[75, 124, "CHALLENGE"], [130, 176, "CHALLENGE"], [181, 225, "CHALLENGE"]]}
" Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia", {"entities": [[7, 28, "CHALLENGE"], [30, 37, "CHALLENGE"], [39, 54, "CHALLENGE"], [60, 66, "CHALLENGE"]]}
" However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality", {"entities": [[41, 73, "CHALLENGE"], [91, 172, "CHALLENGE"], [173, 215, "CHALLENGE"]]}
" Some of these are related to the research process, for example, confidentiality and informed consent in association with human tissue sampling", {"entities": [[65, 80, "CHALLENGE"], [85, 101, "CHALLENGE"]]}
" Concerns regarding confidentiality and discrimination were stated", {"entities": [[20, 35, "CHALLENGE"], [40, 54, "CHALLENGE"]]}
" Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks", {"entities": [[41, 57, "CHALLENGE"], [62, 77, "CHALLENGE"], [101, 109, "CHALLENGE"], [111, 118, "CHALLENGE"], [124, 130, "CHALLENGE"]]}
"0% of online news articles mentioned testing confidentiality and privacy protection", {"entities": [[45, 60, "CHALLENGE"], [65, 83, "CHALLENGE"]]}
" Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing", {"entities": [[35, 42, "CHALLENGE"], [44, 59, "CHALLENGE"], [61, 69, "CHALLENGE"], [71, 87, "CHALLENGE"], [89, 113, "CHALLENGE"], [115, 122, "CHALLENGE"]]}
" (Genetics 1987; 117:343-351) and hierarchical clustering of haplotypes as described by Durrant et al", {"entities": [[34, 57, "ANALYTICAL_METHOD"]]}
" Results: Using unsupervised hierarchical clustering and a combination of candidate genotypes and clinical variables, we identified several distinct clusters of patients at high risk (36-38%) and low risk (10-17%) of respiratory depression; the relative risk of respiratory depression for high versus low risk clusters was 2", {"entities": [[16, 52, "ANALYTICAL_METHOD"]]}
" Hierarchical clustering of the common genes represented in both mRNA and protein datasets displayed two dominant patterns", {"entities": [[1, 24, "ANALYTICAL_METHOD"]]}
" Identification of groups of features is performed by hierarchical clustering", {"entities": [[54, 77, "ANALYTICAL_METHOD"]]}
" This chapter presents a workflow to interrogate multiple genomic inputs and individually assess their relationship with the phenotype of drug resistance using hierarchical clustering to determine the set of features that can best describe what features are associated with drug resistance", {"entities": [[160, 183, "ANALYTICAL_METHOD"]]}
" In the near future, we envision a shift toward long-read sequencing as the predominant method for gene diagnostics and pharmacogenetic profiling, providing unprecedented data quality and improving patient care", {"entities": [[48, 68, "TECHNIQUE"]]}
" Here, we show the utility of long-read sequencing to resolve complex pharmacogenes by analyzing a well-characterised sample", {"entities": [[30, 50, "TECHNIQUE"]]}
" Together, these findings suggest that long-read sequencing data offers promising opportunities in elucidating complex pharmacogenes and haplotype phasing while maintaining accurate variant calling", {"entities": [[39, 59, "TECHNIQUE"]]}
" Long-read sequencing, on the other hand, has been shown to be able to resolve complex (pharmaco) genes", {"entities": [[1, 21, "TECHNIQUE"]]}
" In this study we aimed to assess the value of long-read sequencing for research and clinical PGx focusing on the important and highly polymorphic <i>CYP2C19</i> gene", {"entities": [[47, 67, "TECHNIQUE"]]}
" <b>Methods and Results:</b> With a capture-based long-read sequencing panel we were able to characterize the entire region and assign variants to their allele of origin (phasing), resulting in the identification of 813 unique variants in 37 samples", {"entities": [[50, 70, "TECHNIQUE"]]}
" To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci", {"entities": [[62, 82, "TECHNIQUE"], [111, 140, "TECHNIQUE"]]}
" Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing", {"entities": [[140, 160, "TECHNIQUE"], [162, 182, "TECHNIQUE"], [188, 207, "TECHNIQUE"]]}
" In this study, we employed long-read sequencing technology, extensively utilized in studying complex genomic regions, to characterize genetic alterations, including short variants (single nucleotide variants and short insertions and deletions) and copy number variations, in 370 CMRGs across 41 individuals from 19 global populations", {"entities": [[28, 48, "TECHNIQUE"]]}
" We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data", {"entities": [[178, 183, "DATABASE"], [185, 189, "DATABASE"], [194, 200, "DATABASE"]]}
" While sequence data about genetic variation is found at databases such as dbSNP, clues about the functional and phenotypic consequences of the variations are generally found in biomedical literature", {"entities": [[75, 80, "DATABASE"]]}
" We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser", {"entities": [[53, 57, "DATABASE"], [148, 153, "DATABASE"], [235, 239, "DATABASE"], [282, 284, "DATABASE"], [314, 318, "DATABASE"], [362, 366, "DATABASE"], [523, 530, "DATABASE"], [566, 574, "DATABASE"], [609, 613, "DATABASE"], [663, 682, "DATABASE"]]}
"While it is arguably the most comprehensive source of genetic information, the NCBI's dbSNP database (National Center for Biotechnology Information database of single nucleotide polymorphisms; http://www", {"entities": [[86, 91, "DATABASE"]]}
" Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases", {"entities": [[15, 21, "DATABASE"], [48, 57, "DATABASE"], [59, 66, "DATABASE"], [68, 74, "DATABASE"], [76, 81, "DATABASE"], [83, 87, "DATABASE"], [89, 97, "DATABASE"], [99, 106, "DATABASE"], [112, 121, "DATABASE"]]}
" We compare and report here on the observed SNP genetic variation in our sample with data on 12 world populations from dbSNP and discuss the feasibility of forecasting the pharmacokinetics of drugs utilized by migrant communities in Mersin and the Eastern Mediterranean region", {"entities": [[119, 124, "DATABASE"]]}
" In total, 18,245 variants were identified of which 2565 were novel variants (without rs number in dbSNP build 150) in the testing phase", {"entities": [[99, 104, "DATABASE"]]}
" Our results demonstrate that nanopore sequencing is an emerging standalone technology with potential utility in a clinical environment to aid in medical decision-making", {"entities": [[30, 49, "TECHNIQUE"]]}
" We have established methods for sequencing and haplotyping of the whole <i>CYP2D6</i> gene using nanopore sequencing", {"entities": [[98, 117, "TECHNIQUE"]]}
"The MinION nanopore sequencing device opens the opportunity to cost-effective and point-of-care DNA sequencing", {"entities": [[4, 30, "TECHNIQUE"]]}
" We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples", {"entities": [[16, 24, "TECHNIQUE"], [79, 98, "TECHNIQUE"]]}
"Nanopore sequencing has been examined as a method for rapid and high-resolution human leukocyte antigen (HLA) typing in recent years", {"entities": [[0, 19, "TECHNIQUE"]]}
" This work advances the use of nanopore sequencing in clinical PGx settings", {"entities": [[31, 50, "TECHNIQUE"]]}
" Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing", {"entities": [[140, 160, "TECHNIQUE"], [162, 182, "TECHNIQUE"], [188, 207, "TECHNIQUE"]]}
" <b>Objectives:</b> We sought to develop a Nanopore sequencing panel and validate its performance in patients with active tuberculosis (TB) to personalize treatment dosing", {"entities": [[43, 62, "TECHNIQUE"]]}
" <b>Methods:</b> We developed a Nanopore sequencing panel targeting 15 SNPs in five genes affecting the metabolism of antitubercular drugs", {"entities": [[32, 51, "TECHNIQUE"]]}
" Finally, structural analysis and molecular dynamics simulation indicated that TPMT*27 was less stable than was the wild type TPMT allozyme", {"entities": [[34, 52, "ANALYTICAL_METHOD"]]}
" We used molecular dynamics (MD) simulation to predict the structure of the complex of human TPMT-AdoHcy(CH(2))6MP, where the sulfur atoms of AdoHcy and 6MP were linked by a CH(2) group", {"entities": [[9, 27, "ANALYTICAL_METHOD"]]}
" Molecular dynamics simulation (MDS) approach was conducted to investigate conformational changes in the mutant protein structure with respect to its native conformation", {"entities": [[1, 20, "ANALYTICAL_METHOD"]]}
" The bfPGRP1-ligand complex molecular dynamics simulation followed by free binding energy (BE) computation conceded BE values of -18", {"entities": [[28, 47, "ANALYTICAL_METHOD"]]}
" We had applied molecular dynamics simulation to study the possible conformational changes induced by Lys256Arg transversion on the overall structure of integrin and we have analyzed the binding affinities of natalizumab in the non-mutated and mutated structures through HINT score", {"entities": [[16, 34, "ANALYTICAL_METHOD"]]}
" In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches", {"entities": [[148, 165, "ANALYTICAL_METHOD"], [170, 188, "ANALYTICAL_METHOD"]]}
"Gly187Trp mutant embedded in different lipid bilayers and relaxed them for hundreds of nanoseconds by molecular dynamics simulations", {"entities": [[102, 120, "ANALYTICAL_METHOD"]]}
" Molecular dynamics results validated the stable conformation of oridonin docking pose on Akt kinase domain", {"entities": [[1, 19, "ANALYTICAL_METHOD"]]}
" Further, the mutant displayed enhanced structural flexibility particularly in the low density lipoprotein (LDL) binding domain, decreased solvent accessibility of catalytic residues-Phe274 and Ser273 and increased C\u0251 distance between Phe274 and Leu153 and large conformational entropy change as inferred from all-atom molecular dynamics (MD) simulation and essential dynamics (ED) studies", {"entities": [[319, 337, "ANALYTICAL_METHOD"]]}
" Further, the effect of amino acid substitutions CYP2C9 variants on the protein flexibility in the presence of tamoxifen in 4-hydroxy orientation was evaluated by molecular dynamics (MD) simulations", {"entities": [[163, 181, "ANALYTICAL_METHOD"]]}
" Besides, the influence of rs1065852 on the structure of CYP2D6 was further investigated via molecular dynamics simulations", {"entities": [[93, 111, "ANALYTICAL_METHOD"]]}
" Molecular dynamics simulations revealed higher overall flexibility, decreased intramolecular hydrogen bonds and lower content of regular secondary structures for both cancer driver variants G73W and F432S when compared to the wild-type structure", {"entities": [[1, 19, "ANALYTICAL_METHOD"]]}
" We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins", {"entities": [[34, 52, "ANALYTICAL_METHOD"], [62, 85, "ANALYTICAL_METHOD"]]}
" Five missense variants were modeled and microsecond scale molecular dynamics simulations were conducted for each, as well as for the CYP3A5 wildtype and the Y53C variant, which has a known deleterious impact on enzyme activity", {"entities": [[59, 77, "ANALYTICAL_METHOD"]]}
" Here we have evaluated spatio-temporal functional and molecular dynamics of five PDO models established after hepatic re-resections and neoadjuvant combination chemotherapies in a patient with microsatellite stable and KRAS mutated metastatic rectal cancer", {"entities": [[55, 73, "ANALYTICAL_METHOD"]]}
" We show how computational approaches such as bioinformatics tools and molecular dynamics simulations can be used to characterize the variant receptors in comparison to the wildtype receptor", {"entities": [[71, 89, "ANALYTICAL_METHOD"], [46, 66, "NO_ENTITY"]]}
" Moreover, the stability behavior of selected docked complexes (drugs-EWS) was checked by molecular dynamics simulations", {"entities": [[90, 108, "ANALYTICAL_METHOD"]]}
" Finally, molecular dynamics simulations were used to investigate the stability of the best selected docked complexes", {"entities": [[10, 28, "ANALYTICAL_METHOD"]]}
" Further, the molecular dynamics simulations were performed to comprehend the conformational changes and stability of the targets upon binding of the selected top ranked RA drug", {"entities": [[14, 32, "ANALYTICAL_METHOD"]]}
" As a result, the five best flavonoid-docked complexes were selected and further evaluated by Molecular Dynamics (MD) simulation studies at 100 ns", {"entities": [[94, 112, "ANALYTICAL_METHOD"]]}
" <b>Results:</b> Normal mode analysis and molecular dynamics highlight the effects of known CYP missense variants on protein stability and conformational dynamics", {"entities": [[42, 60, "ANALYTICAL_METHOD"]]}
" Molecular dynamics simulations revealed large conformational fluctuations, confirming the predicted reduced function of <i>*86</i> and <i>*113</i> alleles", {"entities": [[1, 19, "ANALYTICAL_METHOD"]]}
"In the past decade, pharmacogenomics and microarrays are considered two of the most important scientific breakthroughs for detection and treatment of diseases with many other applications", {"entities": [[41, 52, "TECHNIQUE"], [20, 36, "NO_ENTITY"]]}
" The IC50 values for miltirone of 60 National Cancer Institute cell lines were associated with the microarray-based expression of 9,706 genes", {"entities": [[99, 109, "TECHNIQUE"]]}
" The results obtained from microarray were further validated by real-time reverse transcription-PCR", {"entities": [[27, 37, "TECHNIQUE"]]}
"The pharmacogenomic effects of a corticosteroid (CS) were assessed in rat skeletal muscle using microarrays", {"entities": [[96, 107, "TECHNIQUE"]]}
" These technologies include target therapies, toxicogenomics, nanomedicine, pharmacogenetics and pharmacogenomics, with a particular focus on microarray technology", {"entities": [[142, 152, "TECHNIQUE"]]}
" Improvements in the sensitivity and precision of DNA microarrays permit a detailed and accurate scrutiny of the human genome", {"entities": [[50, 65, "TECHNIQUE"]]}
"Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research", {"entities": [[38, 52, "TECHNIQUE"], [68, 85, "ANALYTICAL_METHOD"], [110, 121, "ANALYTICAL_METHOD"]]}
" The progress of molecular biology with particular consideration of genotyping and DNA microarray technologies has created a basis for the dynamic progress of pharmacogenetics, allowing fast and sensitive determination of the individual pharmacogenetic profile, encompassing a large set of CYP alleles extended by allelic variants of genes encoding other enzymes participating in drug metabolism", {"entities": [[83, 97, "ANALYTICAL_METHOD"]]}
" However, the comprehensive study of pharmacoepigenomics awaits the advent of genome-wide analysis of DNA methylation using microarrays and next-generation sequencers", {"entities": [[102, 135, "TECHNIQUE"], [140, 166, "TECHNIQUE"]]}
"Novel multistranded and alternative DNA, RNA and plasmid microarrays (transitional structural nucleic acid microarrays) have been developed that allows for the immobilization of intact, nondenatured, double-stranded DNA, double-stranded RNA, and alternative and multistranded nucleic acids", {"entities": [[41, 68, "TECHNIQUE"]]}
" This technology represents the next generation of microarrays, which will aid in the characterization of nucleic acid structure and function, and accelerate the discovery of drugs that bind to nucleic acids", {"entities": [[51, 62, "TECHNIQUE"]]}
" These novel nucleic acid microarrays, together with pharmacogenomics, can be used to improve the study of DNA and RNA structure, gene expression, drug development and treatment of various diseases", {"entities": [[13, 37, "TECHNIQUE"]]}
" It is suggested that a systems biology approach employing microarray analyses of gene expression and methylation patterns can lead to a better understanding of long-term side-effects of drugs, and that in the future, epigenetic assays should be incorporated into the safety assessment of all pharmaceutical drugs", {"entities": [[59, 69, "TECHNIQUE"]]}
" In addition to high-density experimental microarrays, low-density, gel-based biochip technology represents a versatile platform for translation of research into clinical practice", {"entities": [[42, 53, "TECHNIQUE"], [68, 85, "TECHNIQUE"]]}
" Gel-based microarrays (biochips) consist of nanoliter gel drops on a hydrophobic surface with different immobilized biopolymers (primarily nucleic acids and proteins)", {"entities": [[1, 22, "TECHNIQUE"]]}
" In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling", {"entities": [[43, 64, "TECHNIQUE"]]}
" Research into gene diversity through single-nucleotide polymorphisms (SNPs) by means of microarray systems, allows the detailed analysis of gene factors associated to a given disease", {"entities": [[89, 99, "TECHNIQUE"]]}
" Screening of microarray data revealed paraoxonases PON1 and PON3 among 17 candidate esterases", {"entities": [[14, 24, "TECHNIQUE"]]}
" Potential explanations for low replication rate include differences in microarray platforms, statistical modeling, covariates considered and origin and collection procedures of tissues", {"entities": [[72, 82, "TECHNIQUE"], [94, 114, "ANALYTICAL_METHOD"]]}
"The advent of microarrays over the past decade has transformed the way genome-wide studies are designed and conducted, leading to an unprecedented speed of acquisition and amount of new knowledge", {"entities": [[14, 26, "TECHNIQUE"]]}
" Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters", {"entities": [[1, 11, "TECHNIQUE"]]}
" Herein, we present a summary of the main applications of whole-genome expression microarrays in the field of molecular-targeted therapies for solid tumors and we discuss their potential in the clinical setting", {"entities": [[82, 93, "TECHNIQUE"]]}
" Increasing numbers of clinically useful DNA microarrays are in the development stage, including a simplified procedure for genotyping patients for CYP2D6, which metabolizes a high proportion of the currently prescribed antidepressants and antipsychotics", {"entities": [[41, 56, "TECHNIQUE"]]}
"We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes", {"entities": [[200, 234, "TECHNIQUE"], [175, 190, "TECHNIQUE"]]}
" Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants", {"entities": [[1, 43, "TECHNIQUE"], [58, 78, "ANALYTICAL_METHOD"]]}
" Selected phytochemicals from Korean plants were analyzed in more detail using microarray-based mRNA expression profiles and molecular docking to VEGFR1 and VEGFR2", {"entities": [[79, 120, "TECHNIQUE"]]}
" By using COMPARE analysis of microarray-based transcriptome-wide mRNA expressions, 21 genes were found to significantly correlate with response of 60 tumor cell lines to cantharidin", {"entities": [[30, 82, "TECHNIQUE"]]}
" For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel", {"entities": [[43, 73, "ANALYTICAL_METHOD"], [80, 131, "TECHNIQUE"]]}
" With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution", {"entities": [[66, 78, "TECHNIQUE"], [34, 65, "TECHNIQUE"], [80, 91, "TECHNIQUE"], [93, 119, "TECHNIQUE"], [125, 147, "TECHNIQUE"]]}
" We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial", {"entities": [[17, 51, "ANALYTICAL_METHOD"], [53, 57, "ANALYTICAL_METHOD"], [79, 101, "TECHNIQUE"]]}
" cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers were all modified by OGE treatment", {"entities": [[1, 22, "TECHNIQUE"]]}
" We report an electrolytic plating procedure to fabricate low-density gold microarrays on PCB suitable for electrochemical DNA detection in research fields such as cancer diagnostics or pharmacogenetics, where biosensors are usually targeted to detect a small number of genes", {"entities": [[75, 86, "NO_ENTITY"]]}
" The surface of the microarray is functionalized with self-assembled monolayers of mercaptoundodecanoic acid or thiolated DNA", {"entities": [[20, 30, "TECHNIQUE"]]}
"To develop a gold nanoparticle-based visual DNA microarray for simple and rapid screening of EGFR gene mutations", {"entities": [[44, 58, "TECHNIQUE"]]}
" The progress of molecular biology tools (microarrays, proteomics and nanotechnology) have revolutionised the field of the biomarker discovery", {"entities": [[42, 53, "TECHNIQUE"], [55, 65, "NO_ENTITY"], [70, 84, "NO_ENTITY"]]}
" Understanding the process microarray testing provides a framework for understanding pharmacogenetic testing", {"entities": [[27, 37, "TECHNIQUE"]]}
" The progress of molecular biology tools (microarrays, proteomics, and epigenetics) have progressed the field of the genetic markers discovery", {"entities": [[42, 53, "TECHNIQUE"], [55, 65, "NO_ENTITY"], [71, 82, "NO_ENTITY"]]}
" DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NF\u03baB as potential transcription factor involved in cryptotanshinone's mode of action", {"entities": [[1, 18, "ANALYTICAL_METHOD"], [35, 45, "TECHNIQUE"]]}
" Transcriptomic data were obtained from these samples using Illumina HumanHT-12 v4 Expression BeadChip microarrays", {"entities": [[83, 114, "TECHNIQUE"]]}
" Validation of expression of selected candidate genes was determined by evaluating an independent microarray expression data set", {"entities": [[98, 119, "TECHNIQUE"]]}
" This study presents two rapid and affordable microarray-based strategies to discriminate three clinically important SNPs in genes ADRA2A, SL6CA2, and OPRM1 (rs1800544, rs5569, and rs1799971, respectively)", {"entities": [[46, 56, "TECHNIQUE"]]}
" Previous studies have relied primarily on microarrays to understand gene expression differences, or have focused on a single tissue or small number of samples", {"entities": [[43, 54, "TECHNIQUE"]]}
"org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments", {"entities": [[230, 236, "TECHNIQUE"], [242, 252, "TECHNIQUE"], [196, 222, "TECHNIQUE"]]}
" Genotyping was performed using the DMET Plus microarray platform", {"entities": [[36, 56, "TECHNIQUE"]]}
" Beg P132 Association of HCV nucleotide polymorphism in the development of hepatocellular carcinoma Mohd Suhail, Abid Qureshi, Adil Jamal, Peter Natesan Pushparaj, Mohammad Al-Qahtani, Ishtiaq Qadri P133 Gene expression profiling by DNA microarrays in colon cancer treated with chelidonine alkaloid Mahmoud Z El-Readi, Safaa Y Eid, Michael Wink P134 Successful <i>in vitro</i> fertilization after eight failed trials Ahmed M", {"entities": [[233, 248, "TECHNIQUE"]]}
" Recent growth in the area of toxicogenomics and pharmacogenomics has provided with a vast amount of drug expression microarray data", {"entities": [[117, 127, "TECHNIQUE"]]}
" Therefore, the miRNA-mRNA interactions and drug toxicity were investigated in silico using available microarray data", {"entities": [[102, 112, "TECHNIQUE"]]}
"As recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings", {"entities": [[94, 104, "TECHNIQUE"]]}
" Microarrays presently remain the technology of choice in applications that require fast, cost-effective genome-wide screening of variants of known importance, particularly for large sample sizes", {"entities": [[1, 12, "TECHNIQUE"]]}
" Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events", {"entities": [[76, 86, "TECHNIQUE"]]}
" Gene expression profiles predicting sensitivity and resistance of tumor cells to induction by curcumin and AA were determined by microarray-based mRNA expressions, COMPARE, and hierarchical cluster analyses", {"entities": [[130, 151, "TECHNIQUE"]]}
" SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively", {"entities": [[55, 65, "TECHNIQUE"], [75, 87, "TECHNIQUE"]]}
" COMPARE analyses of the NCI microarray database for 60 cell lines showed that several genes, including those involved in lipid metabolism, correlated with cellular responsiveness to niclosamide", {"entities": [[29, 39, "TECHNIQUE"]]}
" Forty genes determining cellular responsiveness to As<sub>2</sub>O<sub>3</sub> were identified by microarray and COMPARE analyses in 58 cell lines of the NCI panel", {"entities": [[99, 109, "TECHNIQUE"]]}
" This paper presents the design and the experimentation of a comprehensive software pipeline, named microPipe, for the preprocessing, annotation and analysis of microarray-based Single Nucleotide Polymorphism (SNP) genotyping data", {"entities": [[161, 171, "TECHNIQUE"]]}
" Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics", {"entities": [[1, 12, "TECHNIQUE"], [17, 34, "TECHNIQUE"]]}
" The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction", {"entities": [[147, 157, "TECHNIQUE"]]}
" The optical sensing method in a DNA microarray format was optimized and evaluated for the simultaneous identification of 28 polymorphisms associated with psychiatric pharmacogenomics", {"entities": [[33, 47, "TECHNIQUE"]]}
" Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R", {"entities": [[63, 77, "ANALYTICAL_METHOD"], [81, 92, "TECHNIQUE"], [96, 103, "TECHNIQUE"], [128, 141, "ANALYTICAL_METHOD"], [146, 159, "ANALYTICAL_METHOD"], [160, 176, "ANALYTICAL_METHOD"]]}
" In particular, nonnegative matrix factorization (NMF), with its natural nonnegativity constraints, has demonstrated its ability to extract from 2D microarrays relevant information on specific genes involved in the particular biological process", {"entities": [[16, 48, "ANALYTICAL_METHOD"], [148, 159, "NO_ENTITY"]]}
" Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data", {"entities": [[16, 48, "TECHNIQUE"], [164, 176, "TECHNIQUE"]]}
"33 region was interrogated across deidentified clinical chromosomal microarray (CMA) data from 20,642 patients tested at two academic medical centers", {"entities": [[68, 78, "TECHNIQUE"]]}
" Fourteen patients with chronic ITP were studied by means of microarrays before and during eltrombopag treatment", {"entities": [[61, 72, "TECHNIQUE"]]}
" DNA technologies like the human genome microarray are now partially integrated into clinical practice and are used for developing new \"personalized medicines\" and \"pharmacogenetics\" for improving the efficiency and safety of cancer medications", {"entities": [[1, 17, "NO_ENTITY"], [27, 50, "TECHNIQUE"]]}
" A total of 1,012 whole blood samples collected from Korean subjects were genotyped using the DMET\u2122 plus microarray", {"entities": [[94, 115, "TECHNIQUE"]]}
" The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling", {"entities": [[285, 288, "TECHNIQUE"], [293, 304, "TECHNIQUE"]]}
"To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts", {"entities": [[163, 194, "ANALYTICAL_METHOD"], [242, 252, "TECHNIQUE"]]}
" Genotyping was conducted for several <i>DPYD</i>, <i>MTHFR</i> and <i>TYMS</i> polymorphisms using\u00a0a microarray analyzer", {"entities": [[102, 112, "NO_ENTITY"]]}
" The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)", {"entities": [[121, 131, "TECHNIQUE"], [133, 145, "TECHNIQUE"], [158, 175, "TECHNIQUE"]]}
" In this work, we studied the effect of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in HCC by constructing tissue microarrays (TAMs) from 90 HCC cases and corresponding para-cancerous tissues", {"entities": [[132, 143, "TECHNIQUE"]]}
" Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing", {"entities": [[60, 70, "TECHNIQUE"], [72, 98, "TECHNIQUE"], [102, 123, "TECHNIQUE"]]}
" PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan\u2122 microarray (including <i>CYP3A5*3</i> , <i>*6</i> , and <i>*7</i> )", {"entities": [[33, 57, "TECHNIQUE"], [62, 86, "TECHNIQUE"]]}
"This is an overview of drug delivery systems (DDS), starting with various routes of drug administration", {"entities": [[23, 50, "CHALLENGE"]]}
" Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care", {"entities": [[36, 72, "CHALLENGE"], [84, 185, "CHALLENGE"]]}
" Current research should optimise the delivery of this single-agent chemotherapy", {"entities": [[38, 80, "CHALLENGE"]]}
"In this age of personalized medicine, genetic and genomic testing is expected to become instrumental in health care delivery, but little is known about its actual implementation in clinical practice", {"entities": [[130, 198, "CHALLENGE"]]}
" In addition, several drugs for rare diseases have been recently approved or are in late-stage clinical development, and new delivery modalities in cell and gene therapy and oligonucleotide approaches are yielding exciting new medicines for rare diseases of unmet need", {"entities": [[14, 45, "NO_ENTITY"]]}
" Anesthesia providers strive to optimize anesthesia delivery and patient outcomes and to specifically reduce anesthesia-related risks and negative outcomes", {"entities": [[32, 60, "CHALLENGE"], [102, 133, "CHALLENGE"]]}
"Treatment of acute lymphoblastic leukemia (ALL) in adults remains a challenge, as the delivery of intensive chemotherapeutic regimens in this population is less feasible than it is in the pediatric population", {"entities": [[0, 47, "CHALLENGE"]]}
" Subsequently, we address the main hurdles that the healthcare community needs to overcome to expand this model of healthcare delivery and predict how this evolving field will shape future neurologic practice", {"entities": [[139, 208, "NO_ENTITY"]]}
" Furthermore, attendees insisted their providers stay informed of research results that may have an impact on health care delivery", {"entities": [[97, 106, "NO_ENTITY"]]}
" To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness", {"entities": [[83, 126, "CHALLENGE"], [128, 172, "CHALLENGE"], [180, 202, "CHALLENGE"], [204, 242, "CHALLENGE"], [248, 331, "CHALLENGE"], [339, 402, "CHALLENGE"], [407, 453, "CHALLENGE"]]}
" Increased knowledge on the role of ethnicity in PD may help shed light on the symptom expression and treatment response of PD, address inequalities in health care delivery worldwide and improve the delivery of personalised medicine", {"entities": [[136, 172, "CHALLENGE"], [195, 232, "CHALLENGE"]]}
" Nevertheless, the efficacy of siRNA delivery has, so far, remained a challenging issue", {"entities": [[15, 45, "CHALLENGE"]]}
" This is due to their easy degradation through the circulation system and the difficulties in the intracellular delivery to specific tissues where they silence the target genes", {"entities": [[78, 120, "CHALLENGE"]]}
" However, efficient delivery of this information to the point of prescribing remains a significant challenge", {"entities": [[10, 48, "CHALLENGE"]]}
" However, integration of PGx testing may be limited as no uniform approach to delivery of tests has been established and providers are ill-prepared to integrate PGx testing into routine care", {"entities": [[55, 95, "CHALLENGE"], [121, 190, "CHALLENGE"]]}
"Pharmacogenomics (PGx) education is crucial to support the effective delivery of PGx services in any health care system", {"entities": [[0, 32, "CHALLENGE"]]}
" They provide precision delivery of medications based on knowledge of pharmacogenetics, patient and family education related to the meaning of genomics, health and family assessments, and critical feedback and insights on the feasibility of implementing new technologies into clinical point-of-care or community workflows", {"entities": [[226, 298, "CHALLENGE"]]}
" However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce", {"entities": [[65, 98, "CHALLENGE"], [171, 212, "CHALLENGE"]]}
" Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7", {"entities": [[57, 90, "ANALYTICAL_METHOD"], [364, 394, "ANALYTICAL_METHOD"]]}
" Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)", {"entities": [[211, 215, "DATABASE"], [186, 209, "DATABASE"], [93, 116, "TECHNIQUE"], [118, 122, "TECHNIQUE"], [125, 140, "TECHNIQUE"]]}
" When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response", {"entities": [[57, 61, "DATABASE"]]}
" The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network", {"entities": [[15, 39, "TECHNIQUE"], [96, 119, "DATABASE"], [121, 125, "DATABASE"]]}
" Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA)", {"entities": [[151, 174, "DATABASE"], [176, 180, "DATABASE"]]}
" We applied a transcriptome based drug sensitivity prediction method, to the Cancer Genome Atlas (TCGA) ovarian cancer dataset to impute patient tumor response to over 100 different drugs", {"entities": [[77, 96, "DATABASE"], [98, 102, "DATABASE"]]}
" In addition, COAC-inferred subnetworks from melanoma patients' scRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA)", {"entities": [[129, 152, "DATABASE"], [154, 158, "DATABASE"]]}
" Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data", {"entities": [[166, 170, "DATABASE"], [130, 134, "DATABASE"], [93, 128, "DATABASE"], [51, 80, "DATABASE"]]}
" By comparing with the western gastric cancer patients collected from TCGA data portal, some unique characteristics for patients in QTP are suggested", {"entities": [[70, 74, "DATABASE"]]}
" Thirdly, some related genes were identified by intersecting targeted genes, which was predicted by a web tool (miRWalk) and differentially expressed genes, which was obtained from TCGA datasets", {"entities": [[181, 185, "DATABASE"], [112, 119, "NO_ENTITY"]]}
" Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards", {"entities": [[54, 77, "DATABASE"], [85, 112, "DATABASE"], [119, 171, "DATABASE"], [183, 218, "DATABASE"], [219, 223, "DATABASE"], [226, 234, "DATABASE"], [240, 249, "DATABASE"]]}
" <b>Methods:</b> In the present study, we conducted a multi-omics analysis, including gene expression, methylation status, DNA alterations, pharmacogenomics, and survival status based on data from the Cancer Genome Atlas (TCGA) database to discern expression patterns and prognostic roles of BATF in tumors", {"entities": [[222, 226, "DATABASE"], [201, 220, "DATABASE"]]}
" We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)", {"entities": [[91, 95, "DATABASE"], [100, 103, "DATABASE"], [211, 236, "ANALYTICAL_METHOD"], [238, 241, "ANALYTICAL_METHOD"]]}
" Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high <i>MKX-AS1</i> expression status had significantly worse overall survival (HR = 3", {"entities": [[73, 77, "DATABASE"], [52, 71, "DATABASE"]]}
" We applied the model to tumors in The Cancer Genome Atlas (TCGA) dataset and examined associations between predicted cell viability and mutation status or gene expression levels to understand underlying mechanisms of potential value for drug repurposing", {"entities": [[60, 64, "DATABASE"]]}
" <b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics", {"entities": [[100, 123, "DATABASE"], [125, 129, "DATABASE"], [132, 158, "DATABASE"], [160, 164, "DATABASE"], [167, 190, "DATABASE"], [192, 195, "DATABASE"], [206, 225, "DATABASE"], [227, 230, "DATABASE"], [278, 304, "TECHNIQUE"], [306, 315, "TECHNIQUE"], [318, 341, "TECHNIQUE"], [347, 363, "NO_ENTITY"]]}
" The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety", {"entities": [[160, 174, "CHALLENGE"], [195, 218, "CHALLENGE"]]}
" Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues", {"entities": [[25, 59, "CHALLENGE"], [107, 135, "CHALLENGE"], [137, 182, "CHALLENGE"], [184, 222, "CHALLENGE"]]}
" The incorporation of pharmacogenetic/pharmacogenomic protocols into AD research and clinical practice can foster the optimization of therapeutics by helping to develop cost-effective biopharmaceuticals and improving drug efficacy and safety", {"entities": [[161, 202, "CHALLENGE"], [207, 241, "CHALLENGE"]]}
" This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality", {"entities": [[94, 111, "CHALLENGE"]]}
", alcohol intolerance), (ii) reusable graphical interfaces that reduce extension costs, and (iii) explanations of molecular and cellular drug responses", {"entities": [[98, 151, "CHALLENGE"], [29, 86, "CHALLENGE"]]}
"The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear", {"entities": [[0, 50, "NO_ENTITY"], [60, 106, "CHALLENGE"]]}
" Many existing algorithms do not scale up well for large sequences or databases because of their high-computational costs", {"entities": [[29, 66, "CHALLENGE"], [97, 121, "CHALLENGE"]]}
" With the use of molecular criteria and the diminishing cost of analytic technologies, anesthetic practice will become more individualized, and greater emphasis will be placed on the patient's genetic makeup", {"entities": [[44, 85, "CHALLENGE"]]}
" This leads to unnecessarily lengthy processing times and excessive data handling and storage costs", {"entities": [[58, 81, "CHALLENGE"], [86, 99, "CHALLENGE"], [15, 47, "CHALLENGE"]]}
" Clinical trials are ongoing to determine the clinical utility and cost-effectiveness of genotypeguided warfarin dosing", {"entities": [[46, 62, "CHALLENGE"], [67, 85, "CHALLENGE"]]}
" This improvement in survival did come at the cost expectedly of a significant increase in toxicities, including gastrointestinal and hematologic particularly", {"entities": [[46, 61, "NO_ENTITY"]]}
" Along the cost-effectiveness frontier, in relation to clinically dosed warfarin, pharmacogenetics-guided warfarin and apixaban had incremental cost-effectiveness ratios of \u00a313,226 and \u00a320,671 per quality-adjusted life year gained, respectively", {"entities": [[144, 162, "NO_ENTITY"]]}
" On the basis of our simulations, apixaban appears to be the most cost-effective treatment", {"entities": [[66, 80, "NO_ENTITY"]]}
" Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future", {"entities": [[58, 88, "CHALLENGE"]]}
" The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory", {"entities": [[73, 82, "CHALLENGE"], [84, 98, "CHALLENGE"], [103, 119, "CHALLENGE"]]}
" It offers high-accuracy, cost-effective and rapid detection", {"entities": [[11, 24, "CHALLENGE"], [26, 40, "CHALLENGE"], [45, 60, "CHALLENGE"]]}
" Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design", {"entities": [[237, 311, "CHALLENGE"], [330, 371, "CHALLENGE"]]}
" This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities", {"entities": [[87, 109, "CHALLENGE"], [129, 193, "CHALLENGE"]]}
" This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations", {"entities": [[143, 177, "CHALLENGE"]]}
" Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs", {"entities": [[109, 156, "CHALLENGE"], [162, 182, "CHALLENGE"], [79, 107, "CHALLENGE"]]}
"Precision medicine (also called personalized, stratified, or P4 medicine) can be defined as the tailoring of preventive measures and medical treatments to the characteristics of each patient to obtain the best clinical outcome for each person while ideally also enhancing the cost-effectiveness of such interventions for patients and society", {"entities": [[262, 294, "CHALLENGE"]]}
" This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective", {"entities": [[54, 104, "CHALLENGE"]]}
" In order for pharmacogenetics to reach its full potential, more cost-effective and easily accessible genotyping methods are desired", {"entities": [[84, 120, "CHALLENGE"], [65, 79, "CHALLENGE"]]}
" This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment", {"entities": [[82, 111, "CHALLENGE"], [131, 148, "CHALLENGE"]]}
" Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of drugs continues to rise", {"entities": [[79, 110, "NO_ENTITY"]]}
" The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results", {"entities": [[72, 80, "CHALLENGE"], [82, 96, "CHALLENGE"], [101, 117, "CHALLENGE"], [123, 163, "CHALLENGE"]]}
" The costs for both kits are not covered by the statutory health insurance and it is therefore proposed that the patients are invoiced directly in the form of individual healthcare payment", {"entities": [[29, 74, "CHALLENGE"]]}
" Many laboratories provide these analyses and in individual cases the costs are reimbursed by the statutory health insurance", {"entities": [[70, 75, "NO_ENTITY"]]}
"DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics", {"entities": [[92, 123, "CHALLENGE"], [214, 238, "CHALLENGE"], [240, 257, "CHALLENGE"], [262, 271, "CHALLENGE"]]}
" Large-scale epidemiologic studies are required to demonstrate the usefulness and cost-effectiveness of screening tests because their efficacy is affected by the genetic differences among ethnicities", {"entities": [[162, 199, "CHALLENGE"]]}
" PGx testing that is preemptive, adaptable, current, and executable (PACE) overcomes the human and technological barriers to successful implementation, thus capitalizing on the affordable cost of such testing and clinical practice guidelines at the point of prescription ordering", {"entities": [[125, 150, "CHALLENGE"], [177, 192, "NO_ENTITY"]]}
"Logistics and (cost-)effectiveness of pharmacogenetic (PGx)-testing may be optimized when delivered through a pre-emptive panel-based approach, within a clinical decision support system (CDSS)", {"entities": [[0, 9, "CHALLENGE"], [14, 34, "CHALLENGE"]]}
" This high-throughput low-cost method accurately determines CNV in the CYP2D6 gene enabling reliable estimates of disease prediction in large epidemiological samples", {"entities": [[101, 165, "CHALLENGE"]]}
" The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a \"genomic era\" of cancer research and treatment", {"entities": [[114, 149, "NO_ENTITY"]]}
" A sufficiently powered prospective study assessing the (cost-)effectiveness of a panel-based pharmacogenomics approach to guide pharmacotherapy is lacking", {"entities": [[56, 119, "CHALLENGE"]]}
" Its utility is also challenged by cost and higher reliance on conventional prescribing practices", {"entities": [[4, 40, "CHALLENGE"]]}
" Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting", {"entities": [[85, 102, "CHALLENGE"], [107, 129, "CHALLENGE"], [147, 188, "CHALLENGE"], [190, 211, "CHALLENGE"], [215, 241, "CHALLENGE"], [243, 261, "CHALLENGE"], [263, 310, "CHALLENGE"], [316, 370, "CHALLENGE"]]}
", improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic", {"entities": [[65, 103, "CHALLENGE"], [105, 159, "CHALLENGE"]]}
" The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs", {"entities": [[99, 155, "CHALLENGE"]]}
" Numerous additional pharmacogenomic associations have been reported concerning antimicrobial-related idiosyncratic adverse drug reactions, particularly involving specific HLA alleles, but, to date, the cost-effectiveness of genotyping prior to prescription has not been confirmed", {"entities": [[225, 257, "CHALLENGE"]]}
" However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements", {"entities": [[61, 87, "CHALLENGE"], [98, 117, "CHALLENGE"], [119, 137, "CHALLENGE"], [143, 167, "CHALLENGE"]]}
" This study aimed to evaluate the cost-effectiveness of preemptive DPYD genotyping to guide fluoropyrimidine therapy in patients with advanced or metastatic CRC", {"entities": [[34, 52, "NO_ENTITY"]]}
"To assess the cost-effectiveness of pharmacogenomics (PGx)-based warfarin (i", {"entities": [[14, 32, "NO_ENTITY"]]}
" In this study we aim to investigate the clinical effectiveness of PGx-guided treatment (occurrence of adverse drug reactions, hospitalisations and re-admissions, polypharmacy) and perform a cost analysis of the intervention", {"entities": [[103, 125, "NO_ENTITY"]]}
" The description of SNPs in pharmacogenes and the establishment of their relationship with the pharmacokinetics of an individual offer an individualized approach that allows us to reduce the unfavorable outcomes of a therapy, ensure better adherence to treatment, prevent the emergence of MDR strains, reduce the cost of treatment, and improve the quality of patients' lives", {"entities": [[46, 128, "CHALLENGE"]]}
" Pharmacogenetic (PGx) screening to guide the choice of antidepressant medication (ADM) in MDD patients yields higher response and remission rates, which could reduce both healthcare and indirect costs", {"entities": [[187, 201, "NO_ENTITY"]]}